



Australian Government

Department of Health, Disability and Ageing

Pharmaceutical Benefits Scheme

Expenditure and Prescriptions Report

1 July 2024 to 30 June 2025

*PBS Analytics and Modelling Section
Reimbursement Strategy Branch
Technology Assessment and Access Division*









Surface mail: Director

PBS Analytics and Modelling Section
Reimbursement Strategy Branch, MDP 900
Department of Health, Disability and Ageing
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Expenditure and Prescription Snapshot - 2024-25

	Government expenditure was \$19.1 billion for the supply of medicines.	This represents 91.7% of total medicine costs and was up 7.4% from 2023-24.
	Patients contributed \$1.7 billion to the cost of their subsidised medicines.	This represents 8.3% of total medicine cost.
	226 million subsidised prescriptions¹ were dispensed.	<p>The number of subsidised prescriptions decreased by 0.2% compared to 2023-24.</p> <p>The average dispensed price² per PBS subsidised prescription was \$91.62 (up from \$85.10 in 2023-24).</p>
	Concession card holders: <ul style="list-style-type: none"> received 196.7 million (87.0%) subsidised prescriptions. accounted for \$11.5 billion (60.2%) of total Government expenditure on medicine. 	<p>Expenditure for this group was up from \$10.8 billion (6.1%) in 2023-24.</p> <p>The average dispensed price for concessional cardholders was \$63.04.</p> <p>The government contributed \$58.35 towards the cost of each concession cardholder medicine on average.</p>
	General patients: <ul style="list-style-type: none"> received 28.9 million (12.8%) subsidised prescriptions accounted for \$7.5 billion (39.2%) of Government expenditure on medicine. 	<p>Expenditure for this group was up from \$6.8 billion (39.2%) in 2023-24.</p> <p>The average dispensed price for general patients³ was \$286.08.</p> <p>The government contributed \$258.65 towards the cost of each general patient medicine on average.</p>
	949 different medicines were listed on the PBS as at 30 June 2025.	These medicines were spread across 5,164 brands.

¹ Includes subsidised prescriptions for concessional cardholders, general patients, and from the Prescriber Bag.

² Patient payment plus Government benefit.

³ General patients hold a Medicare card only and are not concession cardholders.

Detailed information - Contents


Description		Page
Total Expenditure and Prescriptions - Overview		
Figure 1	PBS Expenditure and Prescription Volume, 2005-06 to 2024-25	1
Table 1(a)	PBS Expense accrual, 2023-24 and 2024-25	2
Table 1(b)	PBS Section 100 Programs expense accrual, 2023-24 and 2024-25	2
Table 2(a)	PBS Prescriptions, 2023-24 and 2024-25	3
Table 2(b)	PBS Government Cost, 2023-24 and 2024-25	3
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2023-24 and 2024-25	3
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2023-24 and 2024-25	3
Subsidised Prescriptions and Patient Trends		
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2024-25	4
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2024-25	4
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2023-24 and 2024-25	4
Table 3(d)	Top 25 PBS Drugs (by Active Ingredient) by Patient count, 2024-25	5
Table 3(e)	Top 25 PBS Brands by Patient count, 2024-25	5
Table 3(f)	PBS dispensing by Socio-Economic Indexes for Areas (SEIFA) Decile, 2024-25	6
Figure 2	PBS Dispensing by SEIFA Decile, 2024-25	7
Table 4(a)	PBS Subsidised Prescriptions by Pharmacy State, 2024-25	8
Table 4(b)	PBS Prescriptions by Pharmacy 2023 Modified Monash Model (MMM), 2024-25	9
Figure 3	PBS Prescriptions and Total Cost by Pharmacy MMM, 2024-25	10
Top Drugs/Medicines/Brands		
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) by Highest Government Cost, 2024-25	11
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) by Highest Subsidised Prescriptions, 2024-25	12
Table 5(c)	Top 25 PBS Antineoplastic Drugs (by Active Ingredient) by Highest Government Cost, 2024-25	13
Table 5(d)	Top 25 PBS Biological Products and Drugs by Highest Government Cost, 2024-25	13
Table 5(e)	Top 50 PBS Brands by Highest Government Cost, 2024-25	14
Table 5(f)	Top 50 PBS Brands by Highest Subsidised Prescriptions, 2024-25	15
Table 5(g)	Biosimilar Products and Drugs by Highest Government Cost, 2024-25	16
Table 6(a)	Top 50 PBS Drugs (by Active Ingredient) by Highest Total Prescription Volume, 2024-25	17
Table 6(b)	Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, by Highest Total Prescription Volume, 2024-25	18

Patient Demographics and Residential Aged Care Facilities (RACF)		
Figure 4	Total Government Cost by gender and age-groups, 2024-25	19
Figure 5	Total PBS prescriptions by gender and age-groups, 2024-25	20
Figure 6	PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2024-25	21
Table 6(c)	PBS prescriptions per age group and patient gender, 2024-25	22
Table 6(d)	PBS prescriptions dispensed in a RACF, 2024-25	22
Table 6(e)	Top 10 PBS Drugs (by Active Ingredient) by Highest Government Cost, dispensed in a RACF, 2024-25	23
Table 6(f)	Top 10 PBS Drugs (by Active Ingredient) by Highest Prescriptions, dispensed in a RACF, 2024-25	23
Anatomical Therapeutic Chemical (ATC) Classification and Highest Changes		
Table 7	Top 50 ATC Level 2 Drug Groups by Highest Total Prescription Volume, 2024-25	24
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24 and 2024-25	25
Figure 7(a)	Percentages of subsidised prescriptions for ATC Main Groups, 2024-25	26
Figure 7(b)	Percentages of Government Cost for ATC Main Groups, 2024-25	27
Table 9(a)	Top 35 Drugs by Highest Change to Government Cost, 2023-24 and 2024-25	28
Table 9(b)	Top 35 Drugs by Highest Change to Subsidised Script Volume, 2023-24 and 2024-25	29
Table 9(c)	Top 5 PBS Drugs by Fastest Prescription Growth, 2024-25	30
Table 9(d)	Top 5 PBS Drugs by Fastest Government Cost Growth, 2024-25	30
Table 10(a)	PBS Generic Prescriptions per ATC Level 1, 2024-25	31
Table 10(b)	PBS Generic Prescriptions Percentage Share by ATC Level 1, 2024-25	31
Formularies and Responsible Persons		
Table 11	PBS Prescriptions and Government Cost by Formulary, 2024-25	32
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2024-25	33
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2024-25	34
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2024-25	35
Approved Suppliers and Medicine Statistics		
Table 13	Number of PBS Approved Suppliers, 30 June 2025	36
Table 14(a)	PBS Brand Premiums, 2024-25	36
Table 14(b)	Electronic PBS Prescriptions, 2024-25	36
Table 14(c)	New PBS Drugs (by Active Ingredient), 2024-25	37
Table 14(d)	New PBS Drugs by ATC level 1, 2020-21 to 2023-24	38
Discounted Prescriptions and Continued Dispensing		
Table 15(a)	PBS/RPBS discounted prescriptions dispensed by Community Pharmacies, 2024-25	39
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2024-25	39
Table 16(a)	PBS/RPBS Prescriptions for Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2024-25	40
Table 16(b)	PBS/RPBS Government Cost for Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2024-25	40

Supplements and Appendices		
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17(a)	Remuneration for Community Pharmacies and Friendly Societies for PBS subsidised prescriptions, 2023-24 and 2024-25	41
Table 17(b)	Pharmacy remuneration for PBS prescriptions by Formulary, 2023-24 to 2024-25	42
Table 18	CPA Professional Pharmacy Programs Expenditure, 2024-25	43
Table 19	Actual Costs of Major Components of CPA, 2024-25	44
Table 20	Community Services Obligation (CSO) Expenditure, 2024-25	44
Supplement 2	PBS Information Line Report, 2024-25	45
Supplement 3	National Diabetes Services Scheme (NDSS)	46
Appendix 1	Abbreviations	48
Appendix 2	Technical Notes	49

Figure 1: PBS Expenditure and Prescription Volume, 2005-06 to 2024-25

Section 85 and Section 100 including Prescriber Bag and under co-payment prescriptions*



*Amendments to the Commonwealth of Australia National Health Act 1953 have been enacted that required approved suppliers of Pharmaceutical Benefits Scheme (PBS) medicines to provide the Australian Government, from 1 April 2012, with data on PBS prescriptions that are priced below the general copayment level (under copayment). Details of the legislation enacted on 23 November 2010 can be found in the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2010.

Table 1(a): PBS Expense accrual, 2023-24 and 2024-25

Category	2023-24	Percentage of Total	2024-25	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$8,569,256,355	47.6%	\$9,115,892,233	47.2%	\$546,635,879	6.4%
Section 85 - General	\$4,158,175,163	23.1%	\$4,671,400,086	24.2%	\$513,224,923	12.3%
Prescriber Bag*	\$133,586,768	0.7%	\$135,116,442	0.7%	\$1,529,674	1.1%
Section 100**	\$5,120,564,558	28.4%	\$5,377,077,565	27.8%	\$256,513,007	5.0%
Safety Net Cards	\$22,336,592	0.1%	\$22,374,546	0.1%	\$37,953	0.2%
Total	\$18,003,919,435	100.0%	\$19,321,860,872	100.0%	\$1,317,941,437	7.3%
Total Including Revenue	\$12,671,374,977		\$12,557,684,559		-\$113,690,418	-0.9%

**In 2023-24 dispensing of COVID-19 therapies MOLNUPIRAVIR and NIRMATRELVIR (&) RITONAVIR through Prescriber Bag cost the government over \$120m, in 2024-25 this cost over \$90m

**Individual S100 programs are shown in Table 1(b).

Table 1(b): PBS Section 100 Programs expense accrual, 2023-24 and 2024-25

Category	2023-24	Percentage of Total	2024-25	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs (HSD)	\$2,386,300,078	46.6%	\$2,397,387,289	44.6%	\$11,087,211	0.5%
Chemotherapy (EFC & Chemotherapy-related)	\$2,293,136,731	44.8%	\$2,510,839,867	46.7%	\$217,703,136	9.5%
In Vitro Fertilisation	\$160,849,743	3.1%	\$165,923,754	3.1%	\$5,074,011	3.2%
Opiate Dependence Treatment (ODT) Program*	\$30,593,124	0.6%	-\$1,175,655	0.0%	-\$31,768,779	-103.8%
Aboriginal Health Services (GST exclusive)	\$73,974,778	1.4%	\$86,424,190	1.6%	\$12,449,412	16.8%
Botulinum Toxin Program (incl. Dysport)	\$72,467,223	1.4%	\$77,391,430	1.4%	\$4,924,207	6.8%
Growth Hormone	\$33,389,093	0.7%	\$35,503,628	0.7%	\$2,114,535	6.3%
Paraplegic and Quadriplegic Program	\$63,025	0.0%	\$25,317	0.0%	-\$37,708	-59.8%
Medication Program for Homeless People	\$148,594	0.0%	\$115,970	0.0%	-\$32,624	-22.0%
Closing the Gap (CTG) PBS Co-payment Program	\$69,642,169	1.4%	\$104,641,774	1.9%	\$34,999,605	50.3%
Total	\$5,120,564,558	100.0%	\$5,377,077,565	100.0%	\$256,513,007	5.0%

Note:

Expense figures refer to payments made through the Services Australia and directly from the Department of Health, Disability and Ageing Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

*On 1 July 2023, ODT medicines became part of the Section 100 Highly Specialised Drugs(HSD) Program (Community Access) arrangements. The Australian Government continued to pay pharmaceutical companies directly for ODT medicines supplied to authorised private ODT clinics and other non-PBS dosing sites (including GP clinics) for a transition period of 1 July 2023 to 30 June 2024. The negative expenditure shown for the ODT Program in 2024-25 is due to the over-accrual of 2025 estimated expenses. These were subsequently reversed.

Table 2(a): PBS Prescriptions, 2023-24 and 2024-25

Section 85 and S100, including Prescriber Bag and under co-payment prescriptions

Patient Category	2023-24		2024-25		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	126,080,626	55.7%	125,478,611	55.5%	-602,015	-0.5%
Concessional Safety Net	72,894,256	32.2%	71,183,043	31.5%	-1,711,213	-2.3%
Total Concessional	198,974,882	87.8%	196,661,654	87.0%	-2,313,228	-1.2%
General Non-Safety Net	25,056,143	11.1%	27,040,483	12.0%	1,984,340	7.9%
General Safety Net	2,075,371	0.9%	1,867,165	0.8%	-208,206	-10.0%
Total General	27,131,514	12.0%	28,907,648	12.8%	1,776,134	6.5%
Prescriber Bag	427,312	0.2%	396,218	0.2%	-31,094	-7.3%
Total (Over Co-payment)	226,533,708	100.0%	225,965,520	100.0%	-568,188	-0.3%
Under Co-payment	106,013,367		102,215,744		-3,797,623	-3.6%
Total (Over and Under Co-payment)	332,547,075		328,181,264		-4,365,811	-1.3%

Table 2(b): PBS Government Cost, 2023-24 and 2024-25

Section 85 and S100, including Prescriber Bag, excluding under co-payment prescriptions

Patient Category	2023-24		2024-25		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$7,563,859,940	42.6%	\$8,077,900,620	42.4%	\$514,040,680	6.8%
Concessional Safety Net	\$3,247,898,874	18.3%	\$3,396,893,347	17.8%	\$148,994,473	4.6%
Total Concessional	\$10,811,758,814	60.9%	\$11,474,793,967	60.2%	\$663,035,152	6.1%
General Non-Safety Net	\$6,685,607,220	37.7%	\$7,367,294,603	38.7%	\$681,687,382	10.2%
General Safety Net	\$112,910,921	0.6%	\$109,779,503	0.6%	-\$3,131,417	-2.8%
Total General	\$6,798,518,141	38.3%	\$7,477,074,106	39.2%	\$678,555,965	10.0%
Prescriber Bag*	\$140,589,312	0.8%	\$108,870,654	0.6%	-\$31,718,658	-22.6%
Total (Over Co-payment)	\$17,750,866,267	100.0%	\$19,060,738,727	100.0%	\$1,309,872,460	7.4%

*In 2023-24 dispensing of COVID-19 therapies MOLNUPIRAVIR and NIRMATRELVIR (&) RITONAVIR through Prescriber Bag cost the government over \$120m, in 2024-25 this cost over \$90m.

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2023-24 and 2024-25

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2023-24		2024-25		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	4,018,083	57.3%	3,993,965	57.7%	-24,118	-0.6%
Repatriation Safety Net	2,999,876	42.7%	2,924,237	42.3%	-75,639	-2.5%
Total Repatriation	7,017,959	100.0%	6,918,202	100%	-99,757	-1.4%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2023-24 and 2024-25

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2023-24		2024-25		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$254,648,214	66.1%	\$311,529,842	68.8%	\$56,881,628	22.3%
Repatriation Safety Net	\$130,794,777	33.9%	\$141,154,757	31.2%	\$10,359,979	7.9%
Total Repatriation	\$385,442,991	100.0%	\$452,684,598	100.0%	\$67,241,607	17.4%

Note:

The figures in tables 2(c) and 2(d) will be different than figures currently published in the DVA Annual Report, as expenditure changes due to allowable pharmacy claim adjustments, and processing of historical or delayed claiming by providers.

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2024-25

Section 85 only, including Prescriber Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
2024-25	Concessional Non-Safety Net	123,529,473	\$5,506,656,832	\$911,842,524	\$6,418,499,356	\$51.96
	Concessional Safety Net	70,824,713	\$3,053,456,946	\$0	\$3,053,456,946	\$43.11
	Total Concessional	194,354,186	\$8,560,113,778	\$911,842,524	\$9,471,956,302	\$48.74
	General Non-Safety Net	24,860,135	\$4,381,732,538	\$727,263,321	\$5,108,995,859	\$205.51
	General Safety Net	1,853,283	\$93,727,622	\$13,418,551	\$107,146,173	\$57.81
	Total General	26,713,418	\$4,475,460,160	\$740,681,872	\$5,216,142,032	\$195.26
	Total (excluding Prescriber Bag)	221,067,604	\$13,035,573,938	\$1,652,524,396	\$14,688,098,334	\$66.44
	Prescriber Bag	396,218	\$108,870,654	\$0	\$108,870,654	\$274.77
	Total (including Prescriber Bag)	221,463,822	\$13,144,444,592	\$1,652,524,396	\$14,796,968,988	\$66.81

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2024-25

Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
2024-25	Concessional Non-Safety Net	125,478,611	\$8,077,900,620	\$922,581,083	\$9,000,481,702	\$71.73
	Concessional Safety Net	71,183,043	\$3,396,893,347	\$0	\$3,396,893,347	\$47.72
	Total Concessional	196,661,654	\$11,474,793,967	\$922,581,083	\$12,397,375,049	\$63.04
	General Non-Safety Net	27,040,483	\$7,367,294,603	\$779,425,435	\$8,146,720,037	\$301.28
	General Safety Net	1,867,165	\$109,779,503	\$13,507,094	\$123,286,597	\$66.03
	Total General	28,907,648	\$7,477,074,106	\$792,932,528	\$8,270,006,634	\$286.08
	Total (excluding Prescriber Bag)	225,569,302	\$18,951,868,072	\$1,715,513,611	\$20,667,381,683	\$91.62
	Prescriber Bag	396,218	\$108,870,654	\$0	\$108,870,654	\$274.77
	Total (including Prescriber Bag)	225,965,520	\$19,060,738,727	\$1,715,513,611	\$20,776,252,338	\$91.94

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2023-24 and 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Ave. Price***
2023-24	Jul	18,895,293	9,124,310	28,019,603	\$1,368,529,496	\$124,065,344	\$1,492,594,840	\$78.99
	Aug	20,010,051	9,386,484	29,396,535	\$1,494,359,009	\$120,814,049	\$1,615,173,058	\$80.72
	Sep	18,946,686	8,786,563	27,733,249	\$1,406,268,095	\$107,597,465	\$1,513,865,560	\$79.90
	Oct	19,792,242	8,781,828	28,574,070	\$1,498,030,111	\$106,566,443	\$1,604,596,554	\$81.07
	Nov	20,117,659	8,539,519	28,657,178	\$1,587,758,039	\$102,496,675	\$1,690,254,714	\$84.02
	Dec	21,571,286	8,428,553	29,999,839	\$1,604,511,763	\$98,434,599	\$1,702,946,362	\$78.95
	Jan	16,578,562	8,667,668	25,246,230	\$1,389,516,590	\$166,319,902	\$1,555,836,492	\$93.85
	Feb	17,070,486	8,498,634	25,569,120	\$1,380,293,338	\$169,305,311	\$1,549,598,649	\$90.78
	Mar	17,653,235	8,822,815	26,476,050	\$1,397,466,956	\$171,385,684	\$1,568,852,640	\$88.87
	Apr	18,143,200	8,878,763	27,021,963	\$1,432,364,683	\$164,737,630	\$1,597,102,313	\$88.03
2024-25	May	19,516,012	9,349,855	28,865,867	\$1,598,335,687	\$162,675,124	\$1,761,010,811	\$90.23
	Jun	17,811,684	8,748,374	26,560,058	\$1,452,843,187	\$136,878,884	\$1,589,722,071	\$89.25
Total		226,106,396	106,013,366	332,119,762	\$17,610,276,955	\$1,631,277,111	\$19,241,554,066	\$85.10
2024-25	Jul	19,716,580	9,255,247	28,971,827	\$1,619,436,854	\$138,476,191	\$1,757,913,045	\$89.16
	Aug	19,446,799	9,116,992	28,563,791	\$1,570,659,957	\$128,117,279	\$1,698,777,235	\$87.36
	Sep	18,587,084	8,468,327	27,055,411	\$1,521,712,018	\$115,131,765	\$1,636,843,783	\$88.06
	Oct	20,085,298	8,682,518	28,767,816	\$1,664,882,476	\$117,241,403	\$1,782,123,878	\$88.73
	Nov	19,339,783	8,223,629	27,563,412	\$1,622,403,008	\$107,504,904	\$1,729,907,912	\$89.45
	Dec	21,683,344	8,242,458	29,925,802	\$1,750,743,936	\$107,356,963	\$1,858,100,898	\$85.69
	Jan	16,539,020	8,261,411	24,800,431	\$1,465,821,022	\$167,839,058	\$1,633,660,080	\$98.78
	Feb	16,473,284	7,866,949	24,340,233	\$1,423,019,814	\$165,854,795	\$1,588,874,609	\$96.45
	Mar	18,029,889	8,608,328	26,638,217	\$1,551,019,537	\$179,263,779	\$1,730,283,316	\$95.97
	Apr	17,984,328	8,274,910	26,259,238	\$1,508,268,218	\$169,218,072	\$1,677,486,290	\$93.27
2024-25	May	19,269,771	8,776,561	28,046,332	\$1,653,359,009	\$169,277,804	\$1,822,636,814	\$94.59
	Jun	18,414,122	8,438,414	26,852,536	\$1,600,542,224	\$150,231,599	\$1,750,773,823	\$95.08
Total		225,569,302	102,215,744	327,785,046	\$18,951,868,072	\$1,715,513,611	\$20,667,381,683	\$91.62

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 3(d): Top 25 PBS Drugs (by Active Ingredient) by Patient count, 2024-25

Section 85 and Section 100, including Prescriber Bag

Rank	Drug	Patients	Total Cost
1	AMOXICILLIN	3,561,765	\$84,809,124
2	CEFALEXIN	3,314,969	\$86,082,672
3	AMOXICILLIN + CLAVULANIC ACID	2,295,290	\$59,234,503
4	ROSUVASTATIN	2,132,265	\$287,657,163
5	PANTOPRAZOLE	1,699,346	\$179,519,219
6	ATORVASTATIN	1,433,799	\$193,569,445
7	SALBUTAMOL	1,326,936	\$89,627,610
8	DOXYCYCLINE	1,325,027	\$49,860,780
9	PARACETAMOL + CODEINE	1,314,688	\$69,071,612
10	PREDNISOLONE	1,276,194	\$40,635,146
11	METFORMIN	1,162,767	\$107,696,107
12	OXYCODONE	1,150,946	\$83,542,452
13	ESOMEPRAZOLE	1,132,866	\$141,595,646
14	LEVOTHYROXINE	993,065	\$50,725,392
15	MELOXICAM	932,929	\$42,410,303
16	CELECOXIB	926,813	\$36,156,418
17	PERINDOPRIL	826,481	\$110,811,932
18	ESCITALOPRAM	820,084	\$107,338,219
19	SERTRALINE	774,955	\$103,762,798
20	METHYLPREDNISOLONE	773,767	\$30,308,380
21	DIAZEPAM	769,373	\$31,895,626
22	BUDESONIDE + FORMOTEROL	762,218	\$102,287,833
23	AMLODIPINE	675,228	\$76,456,486
24	BETAMETHASONE DIPROPIONATE	647,851	\$27,902,122
25	DENOSUMAB	646,081	\$319,793,039

Patients cannot be summed to a total as the same patient may receive more than one drug

Table 3(e): Top 25 PBS Brands by Patient count, 2024-25

Section 85 and Section 100, excluding Efficient Funding of Chemotherapy (EFC) and Prescriber Bag

Rank	Brand Name	Drug Name	Patients	Total Cost
1	APO-Cephalexin®	CEFALEXIN	1,476,746	\$35,927,575
2	APO-Amoxycillin®	AMOXICILLIN	1,422,358	\$32,293,474
3	Zempreon CFC-Free with dose counter®	SALBUTAMOL	1,063,475	\$64,951,874
4	Amoxycillin Sandoz®	AMOXICILLIN	1,051,591	\$21,812,015
5	Cefalexin Sandoz®	CEFALEXIN	1,035,985	\$23,657,057
6	Panafcortelone®	PREDNISOLONE	921,564	\$26,596,627
7	Rosuvastatin Sandoz®	ROSUVASTATIN	798,296	\$60,799,197
8	APX-Rosuvastatin®	ROSUVASTATIN	765,410	\$76,180,241
9	APX-Paracetamol/Codeine®	PARACETAMOL + CODEINE	662,373	\$32,789,157
10	Prolia®	DENOSUMAB	636,412	\$292,522,561
11	Eleuphrat®	BETAMETHASONE DIPROPIONATE	610,715	\$26,462,601
12	Pantoprazole Sandoz®	PANTOPRAZOLE	583,293	\$36,936,283
13	Curam Duo Forte 875/125®	AMOXICILLIN + CLAVULANIC ACID	575,134	\$12,240,925
14	APO-Atorvastatin®	ATORVASTATIN	569,759	\$60,150,547
15	APO-AMOXY/CLAV 875/125®	AMOXICILLIN + CLAVULANIC ACID	563,261	\$12,438,349
16	Escitalopram Sandoz®	ESCITALOPRAM	523,425	\$46,239,819
17	Atorvastatin SZ®	ATORVASTATIN	512,950	\$38,758,523
18	Comfarol Forte®	PARACETAMOL + CODEINE	511,008	\$21,205,115
19	Eliquis®	APIXABAN	507,478	\$317,811,361
20	Novasone®	MOMETASONE	496,335	\$17,281,311
21	Ferinject®	FERRIC CARBOXYMALTOSE	494,231	\$159,891,348
22	Staphylex 500®	FLUCLOXACILLIN	493,348	\$14,705,614
23	APX-Doxycycline®	DOXYCYCLINE	487,049	\$16,228,951
24	ROSUVASTATIN-WGR®	ROSUVASTATIN	470,207	\$29,054,031
25	APX-PANTOPRAZOLE®	PANTOPRAZOLE	464,900	\$30,392,719

Patients cannot be summed to a total as the same patient may receive more than one drug or brand

Table 3(f): PBS dispensing by Socio-Economic Indexes for Areas (SEIFA) Decile, 2024-25
Section 85 and Section 100, including Prescriber Bag

SEIFA Decile ¹	Patient Category	Patients ²	Prescriptions	Patient Contribution ³	Patient Net Contribution ⁴	Net Contribution per Script	Government Cost	Government Cost per Patient
1	Concessional incl General Safety Net	621,504	19,706,935	\$93,378,971	\$96,254,528	\$4.88	\$1,069,352,281	\$1,720.59
1	General Non-Safety Net	589,755	6,392,414	\$123,276,553	\$105,904,024	\$16.57	\$330,621,010	\$560.61
1	All patients	1,211,259	26,099,349	\$216,655,524	\$202,158,552	\$7.75	\$1,399,973,291	\$1,155.80
2	Concessional incl General Safety Net	735,814	24,819,848	\$118,865,021	\$122,275,121	\$4.93	\$1,372,796,121	\$1,865.68
2	General Non-Safety Net	842,088	9,448,815	\$184,692,360	\$162,613,753	\$17.21	\$472,449,881	\$561.05
2	All patients	1,577,902	34,268,663	\$303,557,380	\$284,888,874	\$8.31	\$1,845,246,002	\$1,169.43
3	Concessional incl General Safety Net	508,710	17,088,399	\$82,532,684	\$85,308,508	\$4.99	\$966,557,746	\$1,900.02
3	General Non-Safety Net	715,840	7,890,082	\$155,092,203	\$139,309,844	\$17.66	\$393,715,782	\$550.01
3	All patients	1,224,550	24,978,481	\$237,624,888	\$224,618,352	\$8.99	\$1,360,273,527	\$1,110.84
4	Concessional incl General Safety Net	685,581	22,619,474	\$112,354,194	\$116,019,894	\$5.13	\$1,318,644,724	\$1,923.40
4	General Non-Safety Net	1,049,798	11,386,081	\$226,072,908	\$201,553,680	\$17.70	\$593,306,891	\$565.16
4	All patients	1,735,379	34,005,555	\$338,427,102	\$317,573,574	\$9.34	\$1,911,951,615	\$1,101.75
5	Concessional incl General Safety Net	576,542	19,073,677	\$95,860,957	\$98,375,570	\$5.16	\$1,116,616,875	\$1,936.75
5	General Non-Safety Net	1,082,191	11,468,361	\$228,089,690	\$202,678,460	\$17.67	\$600,538,676	\$554.93
5	All patients	1,658,733	30,542,038	\$323,950,647	\$301,054,029	\$9.86	\$1,717,155,550	\$1,035.22
6	Concessional incl General Safety Net	650,005	21,114,310	\$109,819,508	\$112,141,958	\$5.31	\$1,270,757,274	\$1,955.00
6	General Non-Safety Net	1,339,226	13,709,577	\$276,501,411	\$240,142,985	\$17.52	\$724,982,681	\$541.34
6	All patients	1,989,231	34,823,887	\$386,320,918	\$352,284,943	\$10.12	\$1,995,739,955	\$1,003.27
7	Concessional incl General Safety Net	501,928	16,787,951	\$87,714,290	\$90,346,296	\$5.38	\$1,020,262,713	\$2,032.69
7	General Non-Safety Net	1,132,547	11,632,592	\$236,317,252	\$202,691,657	\$17.42	\$643,010,673	\$567.76
7	All patients	1,634,475	28,420,543	\$324,031,542	\$293,037,953	\$10.31	\$1,663,273,385	\$1,017.62
8	Concessional incl General Safety Net	617,545	20,436,849	\$108,738,343	\$112,834,000	\$5.52	\$1,255,770,423	\$2,033.49
8	General Non-Safety Net	1,598,711	15,884,264	\$325,277,079	\$288,385,661	\$18.16	\$899,020,515	\$562.34
8	All patients	2,216,256	36,321,113	\$434,015,421	\$401,219,661	\$11.05	\$2,154,790,938	\$972.27
9	Concessional incl General Safety Net	572,384	19,536,369	\$105,218,712	\$110,542,469	\$5.66	\$1,235,758,389	\$2,158.97
9	General Non-Safety Net	1,658,224	16,877,652	\$350,747,655	\$311,867,661	\$18.48	\$1,010,447,908	\$609.36
9	All patients	2,230,608	36,414,021	\$455,966,366	\$422,410,130	\$11.60	\$2,246,206,297	\$1,006.99
10	Concessional incl General Safety Net	513,082	17,812,450	\$99,529,366	\$105,632,547	\$5.93	\$1,176,166,614	\$2,292.36
10	General Non-Safety Net	2,123,041	22,351,747	\$470,731,321	\$429,423,555	\$19.21	\$1,414,401,471	\$666.21
10	All patients	2,636,123	40,164,197	\$570,260,687	\$535,056,102	\$13.32	\$2,590,568,084	\$982.72
Australia	All patients	18,114,516	326,037,847	3,590,810,477	3,334,302,171	\$10.23	18,885,178,644	\$1,042.54


¹ Based on the SEIFA Index of Relative Socio-economic Advantage and Disadvantage (IRSAD). The IRSAD summarises information about the economic and social conditions of people and households within an area. A low score (1-5) indicates relatively greater disadvantage and a lack of advantage in general, a high score (6-10) indicates a relative lack of disadvantage and greater advantage in general.

² Patients are placed into SEIFA IRSAD Decile based on their residential postcode recorded on their last dispensed prescription. Excludes patient in locations without a SEIFA IRSAD score.

³ The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

⁴ The patient net contribution reflects the amount paid out of pocket by the patient including any discounts, surcharges and specific fees paid by the patient.

Figure 2: PBS Dispensing by SEIFA Decile, 2024-25
Section 85 and Section 100, including Prescriber Bag



The Source of the data is from Table 3(f): PBS dispensing by Socio-Economic Indexes for Areas (SEIFA) Decile, 2024-25

Note:

Based on the SEIFA Index of Relative Socio-economic Advantage and Disadvantage (IRSAD).

General patient out of pocket cost (patient net contribution) increases as the area becomes more advantaged. Patient postcode mapped to Postal Area for SEIFA decile.

More general non-safety net patients, proportional to overall count, access the PBS in more advantaged areas.

Table 4(a): PBS Subsidised Prescriptions by Pharmacy State, 2024-25

Section 85 and Section 100, excluding Prescriber Bag and under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	39,131,013	30,666,383	26,180,149	10,325,638	11,732,638	3,585,232	518,943	1,389,477	123,529,473
Concessional Safety Net	23,405,976	17,491,272	14,713,742	5,974,514	6,195,083	2,156,203	158,441	729,482	70,824,713
General Non-Safety Net	7,851,755	5,993,784	5,187,902	1,563,126	2,908,382	574,399	218,201	562,586	24,860,135
General Safety Net	649,247	440,013	344,819	114,314	204,867	39,723	6,695	53,605	1,853,283
Total	71,037,991	54,591,452	46,426,612	17,977,592	21,040,970	6,355,557	902,280	2,735,150	221,067,604
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	39,762,810	31,168,227	26,572,204	10,475,868	11,901,932	3,630,956	530,887	1,435,727	125,478,611
Concessional Safety Net	23,514,024	17,592,605	14,784,659	6,002,669	6,229,740	2,164,868	159,753	734,725	71,183,043
General Non-Safety Net	8,597,321	6,529,620	5,591,731	1,692,679	3,119,627	606,711	236,118	666,676	27,040,483
General Safety Net	652,955	444,518	347,898	114,908	206,239	39,957	6,731	53,959	1,867,165
Total	72,527,110	55,734,970	47,296,492	18,286,124	21,457,538	6,442,492	933,489	2,891,087	225,569,302
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$1,792,240,326	\$1,355,086,229	\$1,124,939,368	\$462,242,261	\$531,427,654	\$156,414,921	\$21,232,053	\$63,100,603	\$5,506,683,416
Concessional Safety Net	\$996,198,062	\$759,008,015	\$623,768,875	\$261,042,675	\$276,744,371	\$94,969,997	\$5,872,970	\$35,223,313	\$3,052,828,277
General Non-Safety Net	\$1,407,168,002	\$1,171,809,906	\$809,707,617	\$295,385,888	\$475,332,378	\$101,104,986	\$28,413,501	\$92,847,309	\$4,381,769,586
General Safety Net	\$32,182,829	\$22,835,097	\$16,548,224	\$5,983,678	\$10,872,853	\$1,889,168	\$304,505	\$3,090,821	\$93,707,175
Total	\$4,227,789,219	\$3,308,739,247	\$2,574,964,084	\$1,024,654,502	\$1,294,377,257	\$354,379,072	\$55,823,028	\$194,262,046	\$13,034,988,455
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,624,875,438	\$1,929,415,351	\$1,727,521,868	\$664,636,008	\$775,761,451	\$227,248,815	\$31,927,994	\$96,513,696	\$8,077,900,620
Concessional Safety Net	\$1,093,265,968	\$846,200,766	\$702,346,087	\$292,961,182	\$310,491,231	\$106,177,054	\$6,418,314	\$39,032,746	\$3,396,893,347
General Non-Safety Net	\$2,394,746,505	\$1,911,197,972	\$1,408,427,888	\$474,675,213	\$809,260,199	\$147,678,768	\$50,527,271	\$170,780,787	\$7,367,294,603
General Safety Net	\$36,014,085	\$28,086,683	\$19,798,695	\$6,902,577	\$13,011,648	\$2,219,115	\$320,763	\$3,425,936	\$109,779,503
Total	\$6,148,901,996	\$4,714,900,772	\$3,858,094,539	\$1,439,174,979	\$1,908,524,529	\$483,323,752	\$89,194,342	\$309,753,165	\$18,951,868,072
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,914,884,318	\$2,165,391,691	\$1,919,287,349	\$742,270,242	\$862,864,043	\$253,606,146	\$34,925,203	\$107,252,709	\$9,000,481,702
Concessional Safety Net	\$1,093,265,968	\$846,200,766	\$702,346,087	\$292,961,182	\$310,491,231	\$106,177,054	\$6,418,314	\$39,032,746	\$3,396,893,347
General Non-Safety Net	\$2,638,027,747	\$2,109,563,535	\$1,563,712,205	\$524,132,703	\$900,304,108	\$164,349,019	\$55,759,736	\$190,870,983	\$8,146,720,037
General Safety Net	\$40,687,523	\$31,435,182	\$22,228,045	\$7,745,511	\$14,519,370	\$2,492,465	\$349,438	\$3,829,062	\$123,286,597
Total	\$6,686,865,557	\$5,152,591,175	\$4,207,573,687	\$1,567,109,638	\$2,088,178,752	\$526,624,684	\$97,452,691	\$340,985,500	\$20,667,381,683
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,545,140	7,011,123	5,618,765	1,891,670	3,008,697	575,756	262,191	481,677	27,400,013
PBS S85 Subsidised Scripts per Capita	8.31	7.79	8.26	9.50	6.99	11.04	3.44	5.68	8.07
PBS (S85 + S100) Subsidised Scripts per Capita	8.49	7.95	8.42	9.67	7.13	11.19	3.56	6.00	8.23
PBS S85 Govt Cost per Capita	\$494.76	\$471.93	\$458.28	\$541.67	\$430.21	\$615.50	\$212.91	\$403.30	\$475.73
PBS (S85 + S100) Govt Cost per Capita	\$719.58	\$672.49	\$686.64	\$760.80	\$634.34	\$839.46	\$340.19	\$643.07	\$691.67
Population Percentage	31.19%	25.59%	20.51%	6.90%	10.98%	2.10%	0.96%	1.76%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.15%	24.71%	20.97%	8.11%	9.51%	2.86%	0.41%	1.28%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.44%	24.88%	20.36%	7.59%	10.07%	2.55%	0.47%	1.63%	100.00%
Total Cost Percentage	32.35%	24.93%	20.36%	7.58%	10.10%	2.55%	0.47%	1.65%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2024, Source: ABS Publication 3101.04

Table 4(b): PBS Prescriptions by Pharmacy 2023 Modified Monash Model (MMM), 2024-25


Section 85 and Section 100, excluding Prescriber Bag

PBS Prescriptions	1. Metropolitan	2. Regional	3. Large rural	4. Medium rural	5. Small rural	6. Remote	7. Very remote	Australia
Concessional Non-Safety Net	83,583,765	13,054,212	11,948,521	7,695,658	8,373,156	894,622	405,184	125,955,118
Concessional Safety Net	45,752,725	7,166,987	6,830,015	4,888,867	5,865,210	487,245	192,505	71,183,554
General Non-Safety Net	94,381,201	12,385,377	9,897,065	5,583,441	5,113,593	983,924	432,621	128,777,222
General Safety Net	1,236,210	158,712	154,077	126,557	160,097	22,627	10,872	1,869,152
Total	224,953,901	32,765,288	28,829,678	18,294,523	19,512,056	2,388,418	1,041,182	327,785,046
Government Cost	1. Metropolitan	2. Regional	3. Large rural	4. Medium rural	5. Small rural	6. Remote	7. Very remote	Australia
Concessional Non-Safety Net	\$5,884,321,931	\$825,784,838	\$628,085,410	\$346,758,329	\$332,015,343	\$45,188,657	\$15,746,111	\$8,077,900,620
Concessional Safety Net	\$2,247,526,263	\$341,504,512	\$311,923,593	\$214,445,548	\$253,594,551	\$20,078,341	\$7,820,539	\$3,396,893,347
General Non-Safety Net	\$5,904,748,452	\$593,135,478	\$427,660,825	\$203,455,107	\$180,382,750	\$43,810,655	\$14,101,337	\$7,367,294,603
General Safety Net	\$77,398,843	\$8,753,036	\$8,142,497	\$6,223,818	\$7,866,569	\$914,426	\$480,314	\$109,779,503
Total	\$14,113,995,489	\$1,769,177,864	\$1,375,812,325	\$770,882,802	\$773,859,214	\$109,992,078	\$38,148,301	\$18,951,868,072
Total Cost*	1. Metropolitan	2. Regional	3. Large rural	4. Medium rural	5. Small rural	6. Remote	7. Very remote	Australia
Concessional Non-Safety Net	\$6,505,693,387	\$919,088,558	\$713,660,411	\$401,968,677	\$392,738,509	\$50,902,035	\$17,938,207	\$9,001,989,783
Concessional Safety Net	\$2,247,526,263	\$341,504,512	\$311,923,593	\$214,445,548	\$253,594,551	\$20,078,341	\$7,820,539	\$3,396,893,347
General Non-Safety Net	\$7,895,333,268	\$846,488,700	\$629,327,969	\$316,869,335	\$285,281,351	\$63,370,665	\$22,236,294	\$10,058,907,582
General Safety Net	\$86,533,531	\$9,850,193	\$9,203,921	\$7,103,357	\$9,009,598	\$1,059,663	\$533,634	\$123,293,898
Total	\$16,735,086,449	\$2,116,931,963	\$1,664,115,894	\$940,386,917	\$940,624,009	\$135,410,704	\$48,528,674	\$22,581,084,611
Total Cost Percentage	74.11%	9.37%	7.37%	4.16%	4.17%	0.60%	0.21%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Prescriptions (S85 + S100 prescriptions).

Figure 3: PBS Prescriptions and Total Cost by Pharmacy MMM, 2024-25

Section 85 and Section 100, excluding Prescriber Bag



2023 MMM Classifications:

MMM 1 = Metropolitan areas

MMM 2 = Regional centres

MMM 3 = Large rural towns

MMM 4 = Medium rural towns

MMM 5 = Small rural towns

MMM 6 = Remote communities

MMM 7 = Very remote communities

Prescriptions Total Cost

The Source of the data is from Table 4(b): PBS Prescriptions by Pharmacy 2023 Modified Monash Model (MMM), 2024-25

* Total Cost includes cost to the patient and cost to the Government for PBS Prescriptions (S85 + S100 prescriptions).

Table 5(a): Top 50 PBS Drugs (by Active Ingredient) by Highest Government Cost, 2024-25

Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	PEMBROLIZUMAB	78,956	\$669,833,956	\$348,572	\$670,182,528	\$8,488.05
2	ELEXACFTOR + TEZACFTOR + IVACFTOR (&) IVACFTOR	29,267	\$617,774,730	\$391,230	\$618,165,960	\$21,121.60
3	USTEKINUMAB	73,601	\$517,329,069	\$1,750,475	\$519,079,544	\$7,052.62
4	DUPILUMAB	281,099	\$482,137,569	\$6,645,806	\$488,783,375	\$1,738.83
5	AFLIBERCEPT	472,372	\$463,999,619	\$6,259,477	\$470,259,095	\$995.53
6	NIVOLUMAB	57,082	\$409,878,765	\$224,791	\$410,103,556	\$7,184.46
7	SEMAGLUTIDE	2,819,530	\$335,781,950	\$43,607,035	\$379,388,985	\$134.56
8	DENOSUMAB	1,221,393	\$307,397,315	\$12,395,725	\$319,793,039	\$261.83
9	UPADACITINIB	195,775	\$284,746,347	\$4,279,293	\$289,025,640	\$1,476.32
10	APIXABAN	4,235,206	\$274,855,457	\$42,903,353	\$317,758,810	\$75.03
11	OCRELIZUMAB	14,517	\$237,842,536	\$383,559	\$238,226,095	\$16,410.15
12	MOLNUPIRAVIR	185,176	\$223,101,453	\$1,881,306	\$224,982,758	\$1,214.97
13	ADALIMUMAB	390,442	\$221,186,538	\$8,594,869	\$229,781,407	\$588.52
14	DARATUMUMAB	29,631	\$211,485,612	\$421,975	\$211,907,587	\$7,151.55
15	NIRMATRELVIR (&) RITONAVIR	159,771	\$199,764,820	\$2,079,462	\$201,844,282	\$1,263.33
16	OSIMERTINIB	24,290	\$183,410,125	\$392,424	\$183,802,550	\$7,567.00
17	VEDOLIZUMAB	75,266	\$177,155,593	\$1,906,742	\$179,062,335	\$2,379.06
18	LISDEXAMFETAMINE	2,196,214	\$167,623,993	\$54,172,816	\$221,796,809	\$100.99
19	ENZALUTAMIDE	47,550	\$162,218,788	\$540,442	\$162,759,231	\$3,422.91
20	DURVALUMAB	14,875	\$160,804,376	\$75,981	\$160,880,357	\$10,815.49
21	GUSELKUMAB	44,696	\$160,559,636	\$1,042,882	\$161,602,518	\$3,615.59
22	FERRIC CARBOXYMALTOSE	555,410	\$147,545,299	\$12,347,235	\$159,892,534	\$287.88
23	IPILIMUMAB	7,845	\$146,883,368	\$60,333	\$146,943,701	\$18,730.87
24	SACUBITRIL + VALSARTAN	824,477	\$145,846,550	\$9,307,214	\$155,153,764	\$188.18
25	DAROLUTAMIDE	40,789	\$142,784,560	\$564,432	\$143,348,991	\$3,514.40
26	SOFOSBUVIR + VELPATASVIR	11,953	\$142,707,924	\$223,956	\$142,931,879	\$11,957.82
27	TAFAMIDIS	13,922	\$139,381,650	\$135,068	\$139,516,717	\$10,021.31
28	ATEZOLIZUMAB	19,188	\$139,040,633	\$95,710	\$139,136,342	\$7,251.22
29	GLECAPREVIR + PIBRENTASVIR	8,183	\$138,163,255	\$175,328	\$138,338,583	\$16,905.61
30	BUPRENORPHINE	1,554,221	\$131,907,283	\$12,592,594	\$144,499,877	\$92.97
31	ZANUBRUTINIB	16,586	\$130,157,390	\$202,758	\$130,360,148	\$7,859.65
32	CEMIPLIMAB	17,128	\$127,898,582	\$51,818	\$127,950,400	\$7,470.25
33	FARICIMAB	120,397	\$127,146,662	\$1,562,887	\$128,709,549	\$1,069.04
34	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	73,990	\$125,914,513	\$1,723,782	\$127,638,295	\$1,725.07
35	RISANKIZUMAB	23,115	\$122,746,156	\$571,251	\$123,317,407	\$5,334.95
36	ROSUVASTATIN	9,479,981	\$121,191,382	\$48,470,183	\$169,661,565	\$17.90
37	SECUKINUMAB	81,733	\$112,739,882	\$1,831,386	\$114,571,268	\$1,401.77
38	RIVAROXABAN	2,453,795	\$111,816,509	\$28,031,414	\$139,847,923	\$56.99
39	ABEMACICLIB	26,049	\$108,262,393	\$532,032	\$108,794,425	\$4,176.53
40	EMPAGLIFLOZIN	2,034,950	\$105,911,173	\$24,352,494	\$130,263,667	\$64.01
41	RUXOLITINIB	22,952	\$104,090,833	\$321,273	\$104,412,106	\$4,549.15
42	RIBOCICLIB	23,924	\$102,507,600	\$416,674	\$102,924,274	\$4,302.13
43	RAVULIZUMAB	1,612	\$101,141,090	\$41,932	\$101,183,022	\$62,768.62
44	TRASTUZUMAB DERUXTECAN	9,983	\$98,418,216	\$42,397	\$98,460,613	\$9,862.83
45	ATORVASTATIN	7,483,831	\$94,047,268	\$36,382,769	\$130,430,037	\$17.43
46	OFATUMUMAB	39,919	\$92,127,038	\$937,973	\$93,065,012	\$2,331.35
47	GOLIMUMAB	80,230	\$91,422,785	\$1,755,229	\$93,178,014	\$1,161.39
48	ETANERCEPT	108,253	\$89,718,166	\$1,915,090	\$91,633,256	\$846.47
49	PANTOPRAZOLE	7,389,809	\$88,919,819	\$34,719,994	\$123,639,813	\$16.73
50	DAPAGLIFLOZIN	1,915,738	\$87,333,780	\$22,427,280	\$109,761,060	\$57.29

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 5(b): Top 50 PBS Drugs (by Active Ingredient) by Highest Subsidised Prescriptions, 2024-25

Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	ROSUVASTATIN	9,479,981	\$121,191,382	\$48,470,183	\$169,661,565	\$17.90
2	ATORVASTATIN	7,483,831	\$94,047,268	\$36,382,769	\$130,430,037	\$17.43
3	PANTOPRAZOLE	7,389,809	\$88,919,819	\$34,719,994	\$123,639,813	\$16.73
4	ESOMEPRAZOLE	5,335,618	\$71,989,709	\$25,248,354	\$97,238,062	\$18.22
5	APIXABAN	4,235,206	\$274,855,457	\$42,903,353	\$317,758,810	\$75.03
6	PERINDOPRIL	3,708,781	\$46,296,994	\$19,121,539	\$65,418,533	\$17.64
7	METFORMIN	3,682,542	\$49,360,669	\$16,038,472	\$65,399,141	\$17.76
8	AMLODIPINE	3,061,600	\$35,675,185	\$15,017,596	\$50,692,781	\$16.56
9	PREGABALIN	3,012,693	\$47,478,919	\$12,078,839	\$59,557,758	\$19.77
10	SEAGLUTIDE	2,819,530	\$335,781,950	\$43,607,035	\$379,388,985	\$134.56
11	SALBUTAMOL	2,733,615	\$57,652,928	\$11,419,481	\$69,072,410	\$25.27
12	SERTRALINE	2,612,578	\$30,099,142	\$14,212,209	\$44,311,351	\$16.96
13	ESCITALOPRAM	2,571,161	\$29,042,172	\$14,218,459	\$43,260,631	\$16.83
14	MIRTAZAPINE	2,505,111	\$32,294,762	\$11,530,932	\$43,825,695	\$17.49
15	RIVAROXABAN	2,453,795	\$111,816,509	\$28,031,414	\$139,847,923	\$56.99
16	CEFALEXIN	2,397,681	\$27,869,908	\$13,161,829	\$41,031,737	\$17.11
17	CANDESARTAN	2,371,450	\$29,235,478	\$12,335,699	\$41,571,177	\$17.53
18	TELMISARTAN	2,339,779	\$28,481,605	\$12,402,627	\$40,884,232	\$17.47
19	IRBESARTAN	2,240,050	\$27,206,222	\$11,161,811	\$38,368,032	\$17.13
20	LISDEXAMFETAMINE	2,196,214	\$167,623,993	\$54,172,816	\$221,796,809	\$100.99
21	BUDESONIDE + FORMOTEROL	2,124,078	\$64,753,992	\$36,807,905	\$101,561,897	\$47.81
22	OXYCODONE	2,035,208	\$51,080,493	\$11,184,206	\$62,264,700	\$30.59
23	EMPAGLIFLOZIN	2,034,950	\$105,911,173	\$24,352,494	\$130,263,667	\$64.01
24	DAPAGLIFLOZIN	1,915,738	\$87,333,780	\$22,427,280	\$109,761,060	\$57.29
25	PARACETAMOL	1,902,047	\$31,210,185	\$6,590,263	\$37,800,448	\$19.87
26	VENLAFAXINE	1,847,046	\$24,612,995	\$9,727,054	\$34,340,050	\$18.59
27	DUTASTERIDE + TAMSULOSIN	1,838,671	\$50,661,860	\$9,754,589	\$60,416,449	\$32.86
28	BISOPROLOL	1,832,301	\$26,246,374	\$8,098,601	\$34,344,975	\$18.74
29	AMOXICILLIN	1,804,333	\$20,657,743	\$10,647,136	\$31,304,879	\$17.35
30	AMITRIPTYLINE	1,795,971	\$22,656,091	\$8,198,722	\$30,854,813	\$17.18
31	METOPROLOL TARTRATE	1,783,494	\$21,196,667	\$7,785,843	\$28,982,510	\$16.25
32	RAMIPRIL	1,766,683	\$21,526,433	\$8,595,149	\$30,121,582	\$17.05
33	PARACETAMOL + CODEINE	1,729,605	\$40,920,051	\$9,903,801	\$50,823,852	\$29.38
34	METHYLPHENIDATE	1,688,440	\$56,032,037	\$33,025,854	\$89,057,891	\$52.75
35	EZETIMIBE	1,662,752	\$25,636,520	\$7,630,675	\$33,267,195	\$20.01
36	CLOPIDOGREL	1,617,394	\$22,362,882	\$6,735,915	\$29,098,797	\$17.99
37	ATENOLOL	1,601,153	\$19,598,682	\$7,674,709	\$27,273,391	\$17.03
38	RABEPRAZOLE	1,591,895	\$19,804,492	\$7,538,859	\$27,343,351	\$17.18
39	FLUTICASONE PROPIONATE + SALMETEROL	1,571,205	\$54,066,447	\$24,831,609	\$78,898,056	\$50.21
40	BUPRENORPHINE	1,554,221	\$131,907,283	\$12,592,594	\$144,499,877	\$92.97
41	PERINDOPRIL + AMLODIPINE	1,515,973	\$21,038,431	\$8,493,359	\$29,531,789	\$19.48
42	LERCANIDIPINE	1,512,187	\$19,155,339	\$6,930,169	\$26,085,508	\$17.25
43	AMOXICILLIN + CLAVULANIC ACID	1,455,625	\$18,060,172	\$8,116,228	\$26,176,399	\$17.98
44	FUROSEMIDE	1,408,637	\$18,828,950	\$5,404,504	\$24,233,455	\$17.20
45	DULOXETINE	1,380,513	\$19,906,947	\$6,667,805	\$26,574,752	\$19.25
46	OXYCODONE + NALOXONE	1,364,638	\$53,980,551	\$10,352,528	\$64,333,079	\$47.14
47	PREDNISOLONE	1,296,487	\$15,413,086	\$6,092,641	\$21,505,728	\$16.59
48	DIAZEPAM	1,294,595	\$13,539,939	\$6,456,445	\$19,996,384	\$15.45
49	TAPENTADOL	1,293,517	\$44,965,717	\$10,183,736	\$55,149,453	\$42.64
50	DOXYCYCLINE	1,279,915	\$15,813,213	\$6,657,703	\$22,470,916	\$17.56

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 5(c): Top 25 PBS Antineoplastic Drugs (by Active Ingredient) by Highest Government Cost, 2024-25

Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	PEMBROLIZUMAB	78,956	\$669,833,956	\$348,572	\$670,182,528	\$8,488.05
2	NIVOLUMAB	57,082	\$409,878,765	\$224,791	\$410,103,556	\$7,184.46
3	OSIMERTINIB	24,290	\$183,410,125	\$392,424	\$183,802,550	\$7,567.00
4	DARATUMUMAB^^	24,283	\$173,480,135	\$328,506	\$173,808,642	\$7,157.63
5	ENZALUTAMIDE	47,550	\$162,218,788	\$540,442	\$162,759,231	\$3,422.91
6	DURVALUMAB	14,875	\$160,804,376	\$75,981	\$160,880,357	\$10,815.49
7	IPILIMUMAB	7,845	\$146,883,368	\$60,333	\$146,943,701	\$18,730.87
8	DAROLUTAMIDE	40,789	\$142,784,560	\$564,432	\$143,348,991	\$3,514.40
9	ATEZOLIZUMAB	19,188	\$139,040,633	\$95,710	\$139,136,342	\$7,251.22
10	ZANUBRUTINIB	16,586	\$130,157,390	\$202,758	\$130,360,148	\$7,859.65
11	CEMIPLIMAB	17,128	\$127,898,582	\$51,818	\$127,950,400	\$7,470.25
12	ABEMACICLIB	26,049	\$108,262,393	\$532,032	\$108,794,425	\$4,176.53
13	RIBOCICLIB	23,924	\$102,507,600	\$416,674	\$102,924,274	\$4,302.13
14	TRASTUZUMAB DERUXTECAN	9,983	\$98,418,216	\$42,397	\$98,460,613	\$9,862.83
15	RUXOLITINIB^^	17,521	\$82,706,697	\$228,321	\$82,935,018	\$4,733.46
16	NIVOLUMAB + RELATLIMAB	4,440	\$81,029,526	\$48,542	\$81,078,068	\$18,260.83
17	ACALABRUTINIB	10,102	\$74,475,884	\$120,586	\$74,596,470	\$7,384.33
18	PERTUZUMAB	23,046	\$72,511,527	\$135,543	\$72,647,070	\$3,152.26
19	IBRUTINIB	8,900	\$72,145,246	\$102,644	\$72,247,890	\$8,117.74
20	PALBOCICLIB	18,386	\$69,950,269	\$247,697	\$70,197,966	\$3,818.01
21	VENETOCLAX	12,070	\$69,274,394	\$177,859	\$69,452,253	\$5,754.12
22	AVELUMAB	11,631	\$67,371,311	\$30,296	\$67,401,606	\$5,795.00
23	LENALIDOMIDE	48,402	\$60,027,401	\$790,484	\$60,817,885	\$1,256.52
24	OLAPARIB	8,949	\$57,459,915	\$165,319	\$57,625,234	\$6,439.29
25	GOSERELIN^	139,692	\$53,723,088	\$2,843,041	\$56,566,129	\$404.93

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

^ Some of the usage may be for treating other conditions.

^^ Excludes PBS items that are not for cancer treatment.

Table 5(d): Top 25 PBS Biological Products and Drugs by Highest Government Cost, 2024-25

Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	PEMBROLIZUMAB	78,956	\$669,833,956	\$348,572	\$670,182,528	\$8,488.05
2	USTEKINUMAB	73,601	\$517,329,069	\$1,750,475	\$519,079,544	\$7,052.62
3	DUPILUMAB	281,099	\$482,137,569	\$6,645,806	\$488,783,375	\$1,738.83
4	AFLIBERCEPT	472,372	\$463,999,619	\$6,259,477	\$470,259,095	\$995.53
5	NIVOLUMAB	57,082	\$409,878,765	\$224,791	\$410,103,556	\$7,184.46
6	SEMAGLUTIDE	2,819,530	\$335,781,950	\$43,607,035	\$379,388,985	\$134.56
7	DENOSUMAB	1,221,393	\$307,397,315	\$12,395,725	\$319,793,039	\$261.83
8	OCRELIZUMAB	14,517	\$237,842,536	\$383,559	\$238,226,095	\$16,410.15
9	ADALIMUMAB	390,442	\$221,186,538	\$8,594,869	\$229,781,407	\$588.52
10	DARATUMUMAB	29,631	\$211,485,612	\$421,975	\$211,907,587	\$7,151.55
11	VEDOLIZUMAB	75,266	\$177,155,593	\$1,906,742	\$179,062,335	\$2,379.06
12	DURVALUMAB	14,875	\$160,804,376	\$75,981	\$160,880,357	\$10,815.49
13	GUSELKUMAB	44,696	\$160,559,636	\$1,042,882	\$161,602,518	\$3,615.59
14	IPILIMUMAB	7,845	\$146,883,368	\$60,333	\$146,943,701	\$18,730.87
15	ATEZOLIZUMAB	19,188	\$139,040,633	\$95,710	\$139,136,342	\$7,251.22
16	CEMIPLIMAB	17,128	\$127,898,582	\$51,818	\$127,950,400	\$7,470.25
17	FARICIMAB	120,397	\$127,146,662	\$1,562,887	\$128,709,549	\$1,069.04
18	RISANKIZUMAB	23,115	\$122,746,156	\$571,251	\$123,317,407	\$5,334.95
19	SECUKINUMAB	81,733	\$112,739,882	\$1,831,386	\$114,571,268	\$1,401.77
20	RAVULIZUMAB	1,612	\$101,141,090	\$41,932	\$101,183,022	\$62,768.62
21	TRASTUZUMAB DERUXTECAN	9,983	\$98,418,216	\$42,397	\$98,460,613	\$9,862.83
22	OFATUMUMAB	39,919	\$92,127,038	\$937,973	\$93,065,012	\$2,331.35
23	GOLIMUMAB	80,230	\$91,422,785	\$1,755,229	\$93,178,014	\$1,161.39
24	ETANERCEPT	108,253	\$89,718,166	\$1,915,090	\$91,633,256	\$846.47
25	BENRALIZUMAB	26,986	\$85,666,374	\$474,393	\$86,140,767	\$3,192.05

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 5(e): Top 50 PBS Brands by Highest Government Cost, 2024-25

Section 85 and Section 100, excluding under co-payment prescriptions and Efficient Funding of Chemotherapy (EFC)

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	Trikafta®	ELEXACFTOR + TEZACFTOR + IVACFTOR (&) IVACFTOR	29,267	\$617,774,730	\$391,230	\$618,165,960	\$21,121.60
2	Stelara®	USTEKINUMAB	73,601	\$517,329,069	\$1,750,475	\$519,079,544	\$7,052.62
3	Dupixent®	DUPILUMAB	281,098	\$482,135,845	\$6,645,774	\$488,781,619	\$1,738.83
4	Eylea®	AFLIBERCEPT	472,372	\$463,999,619	\$6,259,477	\$470,259,095	\$995.53
5	Ozempic®	SEMAGLUTIDE	2,819,445	\$335,771,645	\$43,605,926	\$379,377,572	\$134.56
6	Rinvoq®	UPADACITINIB	195,774	\$284,745,105	\$4,279,262	\$289,024,367	\$1,476.32
7	Prolia®	DENOSUMAB	1,161,398	\$280,962,599	\$11,559,962	\$292,522,561	\$251.87
8	Eliquis®	APIXABAN	4,235,181	\$274,854,153	\$42,902,906	\$317,757,059	\$75.03
9	Ocrevus®	OCRELIZUMAB	14,517	\$237,842,536	\$383,559	\$238,226,095	\$16,410.15
10	Lagevrio®	MOLNUPIRAVIR	185,173	\$223,098,160	\$1,881,290	\$224,979,450	\$1,214.97
11	Darzalex SC®	DARATUMUMAB	28,363	\$201,645,237	\$418,320	\$202,063,557	\$7,124.20
12	Paxlovid®	NIRMATRELVIR (&) RITONAVIR	159,769	\$199,762,605	\$2,079,446	\$201,842,051	\$1,263.34
13	Tagrisso®	OSIMERTINIB	24,290	\$183,410,125	\$392,424	\$183,802,550	\$7,567.00
14	Entyvio®	VEDOLIZUMAB	75,263	\$177,149,193	\$1,906,647	\$179,055,841	\$2,379.07
15	Vyvanse®	LISDEXAMFETAMINE	2,196,196	\$167,622,616	\$54,172,382	\$221,794,998	\$100.99
16	Xtandi®	ENZALUTAMIDE	47,549	\$162,215,309	\$540,442	\$162,755,752	\$3,422.91
17	Tremfya®	GUSELKUMAB	44,696	\$160,559,636	\$1,042,882	\$161,602,518	\$3,615.59
18	Humira®	ADALIMUMAB	280,376	\$159,513,523	\$6,243,864	\$165,757,387	\$591.20
19	Ferinject®	FERRIC CARBOXYMALTOSSE	555,406	\$147,544,153	\$12,347,196	\$159,891,348	\$287.88
20	Entresto®	SACUBITRIL + VALSARTAN	821,450	\$145,547,791	\$9,256,730	\$154,804,522	\$188.45
21	Nubeqa®	DAROLUTAMIDE	40,786	\$142,773,992	\$564,385	\$143,338,376	\$3,514.40
22	Epclusa®	SOFOSBUVIR + VELPATASVIR	11,953	\$142,707,924	\$223,956	\$142,931,879	\$11,957.82
23	Vyndamax®	TAFAMIDIS	13,922	\$139,381,650	\$135,068	\$139,516,717	\$10,021.31
24	Maviret®	GLECAPREVIR + PIBRENTASVIR	8,183	\$138,163,255	\$175,328	\$138,338,583	\$16,905.61
25	Brkinsa®	ZANUBRUTINIB	16,585	\$130,149,466	\$202,750	\$130,352,216	\$7,859.65
26	Vabysmo®	FARICIMAB	120,397	\$127,146,662	\$1,562,887	\$128,709,549	\$1,069.04
27	Biktarvy®	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	73,990	\$125,914,513	\$1,723,782	\$127,638,295	\$1,725.07
28	Skyrizi®	RISANKIZUMAB	23,114	\$122,740,786	\$571,220	\$123,312,005	\$5,334.95
29	Cosentyx®	SECUKINUMAB	81,733	\$112,739,882	\$1,831,386	\$114,571,268	\$1,401.77
30	Verzenio®	ABEMACICLIB	26,049	\$108,262,393	\$532,032	\$108,794,425	\$4,176.53
31	Jardiance®	EMPAGLIFLOZIN	2,034,932	\$105,910,144	\$24,352,361	\$130,262,505	\$64.01
32	Jakavi®	RUXOLITINIB	22,952	\$104,090,833	\$321,273	\$104,412,106	\$4,549.15
33	Kisqali®	RIBOCICLIB	23,924	\$102,507,600	\$416,674	\$102,924,274	\$4,302.13
34	Ultomiris®	RAVULIZUMAB	1,612	\$101,141,090	\$41,932	\$101,183,022	\$62,768.62
35	Kesimpta®	OFATUMUMAB	39,918	\$92,120,732	\$937,942	\$93,058,674	\$2,331.25
36	Simponi®	GOLIMUMAB	80,229	\$91,421,631	\$1,755,221	\$93,176,852	\$1,161.39
37	Forxiga®	DAPAGLIFLOZIN	1,915,722	\$87,333,046	\$22,427,100	\$109,760,146	\$57.29
38	Fasenra Pen®	BENRALIZUMAB	26,986	\$85,666,374	\$474,393	\$86,140,767	\$3,192.05
39	Nucala®	MEPOLIZUMAB	52,246	\$82,677,980	\$1,021,628	\$83,699,608	\$1,602.03
40	Xarelto®	RIVAROXABAN	1,731,956	\$81,501,830	\$19,643,080	\$101,144,910	\$58.40
41	Ofev®	NINTEDANIB	31,332	\$80,705,221	\$367,044	\$81,072,265	\$2,587.52
42	Crysvita®	BUROSUMAB	3,588	\$78,849,437	\$81,447	\$78,930,884	\$21,998.57
43	Ajovy®	FREMANEZUMAB	145,999	\$78,514,128	\$3,300,493	\$81,814,621	\$560.38
44	Lonquex®	LIPEGFILGRASTIM	68,611	\$76,780,103	\$1,505,168	\$78,285,271	\$1,141.00
45	Lucentis®	RANIBIZUMAB	89,604	\$76,071,358	\$1,071,440	\$77,142,798	\$860.93
46	Mavenclad®	CLADRIBINE	4,232	\$75,749,803	\$97,419	\$75,847,222	\$17,922.31
47	Imbruvica®	IBRUTINIB	8,900	\$72,145,246	\$102,644	\$72,247,890	\$8,117.74
48	CALQUENCE®	ACALABRUTINIB	9,692	\$71,473,445	\$115,538	\$71,588,984	\$7,386.40
49	Botox®	BOTULINUM TOXIN TYPE A	137,690	\$71,193,468	\$3,196,319	\$74,389,787	\$540.27
50	Ryzodeg Penfill®	INSULIN DEGLUDEC + INSULIN ASPART	193,922	\$70,148,164	\$1,946,894	\$72,095,058	\$371.77

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Brand information is based on manufacturer code reported in the PBS Online Claims data.

Brand information is excluded when the code is missing.

Table 5(f): Top 50 PBS Brands by Highest Subsidised Prescriptions, 2024-25
 Section 85 and Section 100, excluding under co-payment prescriptions and EFC

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	Eliquis®	APIXABAN	4,235,181	\$274,854,153	\$42,902,906	\$317,757,059	\$75.03
2	Ozempic®	SEMAGLUTIDE	2,819,445	\$335,771,645	\$43,605,926	\$379,377,572	\$134.56
3	APX-Rosuvastatin®	ROSUVASTATIN	2,708,291	\$34,849,971	\$13,611,664	\$48,461,635	\$17.89
4	APO-Atorvastatin®	ATORVASTATIN	2,511,956	\$32,060,251	\$11,685,427	\$43,745,678	\$17.41
5	Vyvanse®	LISDEXAMFETAMINE	2,196,196	\$167,622,616	\$54,172,382	\$221,794,998	\$100.99
6	Jardiance®	EMPAGLIFLOZIN	2,034,932	\$105,910,144	\$24,352,361	\$130,262,505	\$64.01
7	Zempreon CFC-Free with dose counter®	SALBUTAMOL	2,004,490	\$41,891,842	\$8,033,432	\$49,925,274	\$24.91
8	Forxiga®	DAPAGLIFLOZIN	1,915,722	\$87,333,046	\$22,427,100	\$109,760,146	\$57.29
9	Rosuvastatin Sandoz®	ROSUVASTATIN	1,852,075	\$23,770,135	\$9,400,092	\$33,170,226	\$17.91
10	Xarelto®	RIVAROXABAN	1,731,956	\$81,501,830	\$19,643,080	\$101,144,910	\$58.40
11	APO-Esomeprazole®	ESOMEPRAZOLE	1,606,430	\$21,760,347	\$7,335,042	\$29,095,389	\$18.11
12	Doubluts®	DUTASTERIDE + TAMSULOSIN	1,536,570	\$42,386,584	\$8,101,903	\$50,488,488	\$32.86
13	Lipitor®	ATORVASTATIN	1,469,593	\$18,144,943	\$7,400,855	\$25,545,798	\$17.38
14	Pantoprazole Sandoz®	PANTOPRAZOLE	1,413,773	\$16,674,277	\$6,526,692	\$23,200,969	\$16.41
15	Atorvastatin SZ®	ATORVASTATIN	1,359,320	\$17,130,800	\$6,566,098	\$23,696,898	\$17.43
16	Palexia SR®	TAPENTADOL	1,293,512	\$44,965,541	\$10,183,721	\$55,149,262	\$42.64
17	APX-PANTOPRAZOLE®	PANTOPRAZOLE	1,273,707	\$14,643,649	\$6,476,582	\$21,120,230	\$16.58
18	Crestor®	ROSUVASTATIN	1,188,573	\$14,802,902	\$6,434,457	\$21,237,359	\$17.87
19	APO-Cephalexin®	CEFALEXIN	1,185,522	\$13,804,936	\$6,208,368	\$20,013,304	\$16.88
20	Somac®	PANTOPRAZOLE	1,176,578	\$15,166,280	\$5,968,834	\$21,135,114	\$17.96
21	Prolia®	DENOSUMAB	1,161,398	\$280,962,599	\$11,559,962	\$292,522,561	\$251.87
22	Esopreze®	ESOMEPRAZOLE	1,130,573	\$15,111,220	\$5,340,657	\$20,451,877	\$18.09
23	Sozol®	PANTOPRAZOLE	1,087,355	\$13,110,762	\$4,871,365	\$17,982,126	\$16.54
24	APO-Frusemide®	FUROSEMIDE	1,048,154	\$14,021,691	\$3,966,025	\$17,987,716	\$17.16
25	Cavstat®	ROSUVASTATIN	1,002,368	\$13,009,312	\$4,900,359	\$17,909,671	\$17.87
26	APO-Pregabalin®	PREGABALIN	949,033	\$14,958,676	\$3,727,966	\$18,686,642	\$19.69
27	Escitalopram Sandoz®	ESCITALOPRAM	933,085	\$10,206,356	\$5,280,807	\$15,487,163	\$16.60
28	APO-Sertraline®	SERTRALINE	922,065	\$10,733,795	\$4,901,183	\$15,634,978	\$16.96
29	APX-Mirtazapine®	MIRTAZAPINE	913,730	\$11,831,005	\$4,094,947	\$15,925,952	\$17.43
30	Atorvachol®	ATORVASTATIN	883,273	\$11,312,078	\$4,085,387	\$15,397,464	\$17.43
31	Xalatan®	LATANOPROST	871,047	\$11,531,196	\$4,023,015	\$15,554,211	\$17.86
32	Trajenta®	LINAGLIPTIN	866,746	\$44,364,151	\$7,745,245	\$52,109,395	\$60.12
33	APX-Paracetamol/Codeine®	PARACETAMOL + CODEINE	855,222	\$20,176,145	\$4,747,052	\$24,923,197	\$29.14
34	Hylo-Forte®	HYALURONATE SODIUM	854,186	\$26,132,030	\$4,555,844	\$30,687,874	\$35.93
35	APO-Irbesartan®	IRBESARTAN	824,883	\$10,215,668	\$3,917,341	\$14,133,008	\$17.13
36	Entresto®	SACUBITRIL + VALSARTAN	821,450	\$145,547,791	\$9,256,730	\$154,804,522	\$188.45
37	Osteomol 665 Paracetamol®	PARACETAMOL	816,775	\$13,990,492	\$2,939,275	\$16,929,767	\$20.73
38	APO-Candesartan®	CANDESARTAN	792,999	\$9,856,045	\$4,011,013	\$13,867,058	\$17.49
39	Panafcortelone®	PREDNISOLONE	792,512	\$9,286,089	\$3,822,052	\$13,108,142	\$16.54
40	APO-Perindopril®	PERINDOPRIL	764,751	\$9,602,690	\$3,878,002	\$13,480,691	\$17.63
41	Ritalin LA®	METHYLPHENIDATE	740,811	\$22,096,795	\$16,147,190	\$38,243,985	\$51.62
42	Nexium®	ESOMEPRAZOLE	733,418	\$9,678,056	\$3,680,833	\$13,358,888	\$18.21
43	APO-Telmisartan®	TELMISARTAN	727,621	\$8,944,488	\$3,735,028	\$12,679,516	\$17.43
44	ARDIX GLICLAZIDE 60mg MR®	GLICLAZIDE	721,651	\$10,090,511	\$2,789,657	\$12,880,168	\$17.85
45	Amlodipine Sandoz®	AMLODIPINE	692,617	\$8,034,230	\$3,412,894	\$11,447,123	\$16.53
46	Eleuphrat®	BETAMETHASONE DIPROPIONATE	689,082	\$12,586,163	\$4,943,030	\$17,529,193	\$25.44
47	APO-Amoxycillin®	AMOXICILLIN	686,894	\$8,064,332	\$4,062,314	\$12,126,646	\$17.65
48	Salpraz®	PANTOPRAZOLE	686,070	\$8,292,639	\$3,042,519	\$11,335,158	\$16.52
49	APO-Pantoprazole®	PANTOPRAZOLE	674,203	\$8,458,815	\$2,666,257	\$11,125,072	\$16.50
50	APX-Amitriptyline®	AMITRIPTYLINE	672,532	\$8,593,437	\$2,965,786	\$11,559,223	\$17.19

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 5(g): Biosimilar Products and Drugs by Highest Government Cost, 2024-25

Section 85 and Section 100, excluding under co-payment prescriptions and EFC

Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
Brenzys®	ETANERCEPT	51,657	\$42,933,436	\$885,506	\$43,818,942	\$848.27
Remsima SC®	INFLIXIMAB	43,217	\$24,310,109	\$1,097,740	\$25,407,849	\$587.91
Inflectra®	INFLIXIMAB	29,003	\$23,405,396	\$783,605	\$24,189,001	\$834.02
Hyrimoz®	ADALIMUMAB	34,055	\$19,123,743	\$741,852	\$19,865,595	\$583.34
Amgevita®	ADALIMUMAB	32,087	\$18,144,648	\$681,104	\$18,825,752	\$586.71
Hadlima®	ADALIMUMAB	28,792	\$15,926,792	\$588,988	\$16,515,781	\$573.62
Renflexis®	INFLIXIMAB	17,355	\$14,005,405	\$455,923	\$14,461,329	\$833.27
Ovaleap®	FOLLITROPINALFA	6,595	\$8,755,327	\$200,762	\$8,956,089	\$1,358.01
Novicrit®	EPOETIN LAMBDA	6,539	\$7,172,342	\$71,685	\$7,244,027	\$1,107.82
Yuflyma®	ADALIMUMAB	12,097	\$6,765,930	\$276,494	\$7,042,424	\$582.16
Riximyo®	RITUXIMAB	14,319	\$5,519,285	\$307,044	\$5,826,329	\$406.89
Nivestim®	FILGRASTIM	13,017	\$2,303,595	\$253,612	\$2,557,207	\$196.45
Zarzio®	FILGRASTIM	9,547	\$1,681,370	\$165,981	\$1,847,351	\$193.50
Clexane Forte Safety-Lock®	ENOXAPARINSODIUM	7,798	\$1,447,405	\$123,443	\$1,570,849	\$201.44
Adalicip®	ADALIMUMAB	2,457	\$1,390,452	\$49,969	\$1,440,420	\$586.25
Truxima®	RITUXIMAB	3,532	\$1,318,477	\$84,887	\$1,403,364	\$397.33
Ziextenzo®	PEGFILGRASTIM	15,111	\$1,296,245	\$317,311	\$1,613,556	\$106.78
Terrosa®	TERIPARATIDE	6,829	\$1,166,386	\$78,264	\$1,244,649	\$182.26
Bemfola®	FOLLITROPINALFA	1,024	\$1,160,287	\$31,054	\$1,191,341	\$1,163.42
Pelgraz®	PEGFILGRASTIM	15,001	\$1,108,103	\$388,284	\$1,496,387	\$99.75
Exarane®	ENOXAPARINSODIUM	6,005	\$413,078	\$105,385	\$518,463	\$86.34
Teriparatide Lupin®	TERIPARATIDE	2,183	\$376,241	\$26,401	\$402,642	\$184.44
Abrilada®	ADALIMUMAB	388	\$211,397	\$8,621	\$220,018	\$567.06
Exarane Safety-Lock®	ENOXAPARINSODIUM	2,933	\$172,741	\$54,823	\$227,564	\$77.59
Exarane Forte®	ENOXAPARINSODIUM	408	\$63,819	\$5,016	\$68,835	\$168.71
Idacio®	ADALIMUMAB	78	\$49,051	\$1,633	\$50,684	\$649.80
Exarane Forte Safety-Lock®	ENOXAPARINSODIUM	227	\$36,555	\$3,542	\$40,096	\$176.64
Ruxience®	RITUXIMAB	18	\$5,445	\$252	\$5,697	\$316.51

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing.

Biosimilars included in this report are based on Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme | Australian Government Department of Health, Disability and Ageing. Excluding the reference brand.

Table 6(a): Top 50 PBS Drugs (by Active Ingredient) by Highest Total Prescription Volume, 2024-25
 Section 85 and Section 100, including Prescriber Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
1	ROSUVASTATIN	9,479,981	6,565,517	16,045,498	\$121,191,382
2	ATORVASTATIN	7,483,831	3,630,840	11,114,671	\$94,047,268
3	PANTOPRAZOLE	7,389,809	3,431,283	10,821,092	\$88,919,819
4	ESOMEPRAZOLE	5,335,618	2,461,933	7,797,551	\$71,989,709
5	ESCITALOPRAM	2,571,161	3,897,127	6,468,288	\$29,042,172
6	PERINDOPRIL	3,708,781	2,564,444	6,273,225	\$46,296,994
7	SERTRALINE	2,612,578	3,557,635	6,170,213	\$30,099,142
8	METFORMIN	3,682,542	2,378,323	6,060,865	\$49,360,669
9	CEFALEXIN	2,397,681	2,701,938	5,099,619	\$27,869,908
10	AMOXICILLIN	1,804,333	3,132,889	4,937,222	\$20,657,743
11	AMLODIPINE	3,061,600	1,561,111	4,622,711	\$35,675,185
12	APIXABAN	4,235,206	1,907	4,237,113	\$274,855,457
13	TELMISARTAN	2,339,779	1,739,593	4,079,372	\$28,481,605
14	CANDESARTAN	2,371,450	1,601,685	3,973,135	\$29,235,478
15	PREGABALIN	3,012,693	910,674	3,923,367	\$47,478,919
16	SALBUTAMOL	2,733,615	851,031	3,584,646	\$57,652,928
17	MIRTAZAPINE	2,505,111	1,026,547	3,531,658	\$32,294,762
18	VENLAFAXINE	1,847,046	1,666,956	3,514,002	\$24,612,995
19	AMOXICILLIN + CLAVULANIC ACID	1,455,625	1,935,988	3,391,613	\$18,060,172
20	IRBESARTAN	2,240,050	1,145,971	3,386,021	\$27,206,222
21	OXYCODONE	2,035,208	1,110,402	3,145,610	\$51,080,493
22	AMITRIPTYLINE	1,795,971	1,101,405	2,897,376	\$22,656,091
23	PERINDOPRIL + AMLODIPINE	1,515,973	1,371,035	2,887,008	\$21,038,431
24	DOXYCYCLINE	1,279,915	1,569,981	2,849,896	\$15,813,213
25	PARACETAMOL + CODEINE	1,729,605	1,115,308	2,844,913	\$40,920,051
26	RAMIPRIL	1,766,683	1,054,822	2,821,505	\$21,526,433
27	SEMAGLUTIDE	2,819,530	-	2,819,530	\$335,781,950
28	FLUOXETINE	1,234,158	1,572,615	2,806,773	\$18,100,414
29	BISOPROLOL	1,832,301	675,168	2,507,469	\$26,246,374
30	PREDNISOLONE	1,296,487	1,207,853	2,504,340	\$15,413,086
31	EZETIMIBE	1,662,752	813,403	2,476,155	\$25,636,520
32	RIVAROXABAN	2,453,795	4,495	2,458,290	\$111,816,509
33	MELOXICAM	1,274,582	1,170,288	2,444,870	\$15,672,646
34	RABEPRAZOLE	1,591,895	845,505	2,437,400	\$19,804,492
35	DESVENLAFAXINE	1,216,620	1,208,857	2,425,477	\$21,659,739
36	METOPROLOL TARTRATE	1,783,494	622,931	2,406,425	\$21,196,667
37	DULOXETINE	1,380,513	886,202	2,266,715	\$19,906,947
38	ATENOLOL	1,601,153	657,950	2,259,103	\$19,598,682
39	DUTASTERIDE + TAMSULOSIN	1,838,671	374,684	2,213,355	\$50,661,860
40	LISDEXAMFETAMINE	2,196,214	90	2,196,304	\$167,623,993
41	LEVOTHYROXINE	1,158,570	1,015,225	2,173,795	\$21,112,136
42	BUDESONIDE + FORMOTEROL	2,124,078	22,716	2,146,794	\$64,753,992
43	DIAZEPAM	1,294,595	836,437	2,131,032	\$13,539,939
44	CELECOXIB	1,052,561	1,050,486	2,103,047	\$13,194,300
45	PARACETAMOL	1,902,047	186,095	2,088,142	\$31,210,185
46	CLOPIDOGREL	1,617,394	457,829	2,075,223	\$22,362,882
47	LERCANIDIPINE	1,512,187	543,396	2,055,583	\$19,155,339
48	EMPAGLIFLOZIN	2,034,950	120	2,035,070	\$105,911,173
49	METHYLPHENIDATE	1,688,440	340,904	2,029,344	\$56,032,037
50	DAPAGLIFLOZIN	1,915,738	161	1,915,899	\$87,333,780

Table 6(b): Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, by Highest Total Prescription Volume, 2024-25
Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag



Age Group	Females				Males			
	Drug Name	Prescriptions			Drug Name	Prescriptions		
		PBS Subsidised	Under Co-Payment	Total		PBS Subsidised	Under Co-Payment	Total
Under 18 years old	AMOXICILLIN	172,154	520,321	692,475	METHYLPHENIDATE	863,291	132,010	995,301
	CEFALEXIN	114,963	340,052	455,015	AMOXICILLIN	189,623	562,556	752,179
	METHYLPHENIDATE	351,108	59,995	411,103	LISDEXAMFETAMINE	457,019	30	457,049
	FLUOXETINE	122,583	201,487	324,070	CEFALEXIN	107,367	312,074	419,441
	PREDNISOLONE SODIUM PHOSPHATE	56,451	186,111	242,562	GUANFACINE	414,285	124	414,409
	LISDEXAMFETAMINE	236,243	10	236,253	PREDNISOLONE SODIUM PHOSPHATE	80,882	265,112	345,994
	SERTRALINE	66,924	121,815	188,739	SALBUTAMOL	110,139	137,856	247,995
	SALBUTAMOL	81,458	102,946	184,404	FLUOXETINE	126,616	120,201	246,817
	AMOXICILLIN + CLAVULANIC ACID	45,443	125,308	170,751	FLUTICASONE PROPRIONATE	73,560	155,460	229,020
	FLUTICASONE PROPRIONATE	49,013	102,508	151,521	AMOXICILLIN + CLAVULANIC ACID	52,295	144,507	196,802
TOTAL		1,296,340	1,760,553	3,056,893	TOTAL	2,475,077	1,829,930	4,305,007
18-39 years old	SERTRALINE	354,105	1,074,541	1,428,646	ESCITALOPRAM	136,776	505,472	642,248
	ESCITALOPRAM	292,289	1,026,336	1,318,625	SERTRALINE	144,112	394,446	538,558
	LEVONORGESTREL + ETHINYLESTRADIOL	149,318	653,028	802,346	LISDEXAMFETAMINE	445,377	20	445,397
	FLUOXETINE	206,247	446,181	652,428	AMOXICILLIN	68,576	321,892	390,468
	AMOXICILLIN	162,459	477,800	640,259	CEFALEXIN	60,307	259,577	319,884
	CEFALEXIN	156,368	476,995	633,363	PANTOPRAZOLE	102,030	206,175	308,205
	LISDEXAMFETAMINE	602,652	22	602,674	AMOXICILLIN + CLAVULANIC ACID	59,434	237,879	297,313
	VENLAFAXINE	162,377	289,284	451,661	FLUOXETINE	117,703	175,534	293,237
	AMOXICILLIN + CLAVULANIC ACID	121,749	306,559	428,308	DOXYCYCLINE	51,424	225,118	276,542
	DOXYCYCLINE	103,028	311,707	414,735	MIRTAZAPINE	118,573	149,567	268,140
TOTAL		2,310,592	5,062,453	7,373,045	TOTAL	1,304,312	2,475,680	3,779,992
40-59 years old	ROSUVASTATIN	463,746	1,027,150	1,490,896	ROSUVASTATIN	420,967	1,655,686	2,076,653
	ESCITALOPRAM	338,678	1,057,002	1,395,680	ATORVASTATIN	350,405	887,330	1,237,735
	PANTOPRAZOLE	519,473	745,188	1,264,661	PANTOPRAZOLE	372,392	699,373	1,071,765
	SERTRALINE	335,674	919,284	1,254,958	PERINDOPRIL	209,138	690,028	899,166
	VENLAFAXINE	336,894	577,973	914,867	METFORMIN	260,698	584,556	845,254
	ESOMEPRAZOLE	368,834	536,350	905,184	ESCITALOPRAM	172,913	609,646	782,559
	ESTRADIOL	256,595	564,472	821,067	ESOMEPRAZOLE	229,077	506,603	735,680
	ATORVASTATIN	315,912	492,743	808,655	SERTRALINE	169,981	454,849	624,830
	METFORMIN	291,004	469,531	760,535	PERINDOPRIL + AMLODIPINE	102,604	443,686	546,290
	PERINDOPRIL	204,334	483,247	687,581	TELMISARTAN	81,614	432,608	514,222
TOTAL		3,431,144	6,872,940	10,304,084	TOTAL	2,369,789	6,964,365	9,334,154
60+ years old	ROSUVASTATIN	4,673,713	1,587,495	6,261,208	ROSUVASTATIN	3,830,106	2,081,938	5,912,044
	PANTOPRAZOLE	3,526,232	732,554	4,258,786	ATORVASTATIN	3,396,705	1,310,091	4,706,796
	ATORVASTATIN	3,353,656	836,726	4,190,382	PANTOPRAZOLE	2,693,364	796,000	3,489,364
	ESOMEPRAZOLE	2,835,497	582,861	3,418,358	PERINDOPRIL	1,589,768	748,834	2,338,602
	PERINDOPRIL	1,648,174	506,974	2,155,148	ESOMEPRAZOLE	1,732,541	560,988	2,293,529
	AMLODIPINE	1,587,965	375,894	1,963,859	METFORMIN	1,567,369	642,587	2,209,956
	APIXABAN	1,879,316	435	1,879,751	DUTASTERIDE + TAMUSLOSIN	1,799,739	326,841	2,126,580
	METFORMIN	1,401,781	373,147	1,774,928	APIXABAN	2,010,311	489	2,010,800
	CANDESARTAN	1,305,273	402,720	1,707,993	AMLODIPINE	1,219,905	506,345	1,726,250
	TELMISARTAN	1,264,510	408,700	1,673,210	TELMISARTAN	867,969	481,723	1,349,692
TOTAL		23,476,117	5,807,506	29,283,623	TOTAL	20,707,777	7,455,836	28,163,613

Approximately 0.4% of all prescriptions are excluded due to patient gender being 'X' or unknown patient demographic details.

Reported gender in the PBS Online Claims Data is sourced from Services Australia.

Department of Health, Disability and Ageing does not have access to Medicare personal records.

Figure 4: Total Government Cost by gender and age-groups, 2024-25
Section 85 and Section 100, excluding Prescriber Bag




Approximately 0.4% of all prescriptions are excluded due to patient gender being 'X' or unknown patient demographic details.
Reported gender in the PBS Online Claims Data is sourced from Services Australia.
Department of Health, Disability and Ageing does not have access to Medicare personal records.

The Source of the data is from Table 6(c): PBS prescriptions per age group and patient gender, by Highest Total Prescription Volume, 2024-25


Figure 5: Total PBS prescriptions by gender and age-groups, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag


Total PBS Prescriptions by Gender




Total PBS Prescriptions by Gender and Age-Groups



PBS Subsidised Prescriptions by Gender and Age-Groups




Under Co-Payment Prescriptions by Gender and Age-Groups



The Source of the data is from Table 6(c): PBS prescriptions per age group and patient gender, by Highest Total Prescription Volume, 2024-25

Figure 6: PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag



The Source of the data is from Table 6(d): PBS prescriptions dispensed in a RACF, 2024-25

Table 6(c): PBS prescriptions per age group and patient gender, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Age Group	Patient Gender	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
Under 18 years old	Female	2,733,317	3,077,346	5,810,663	\$390,913,396
Under 18 years old	Male	3,923,329	3,013,556	6,936,885	\$434,871,945
18-39 years old	Female	9,954,928	11,623,072	21,578,000	\$1,433,607,778
18-39 years old	Male	6,216,899	6,947,294	13,164,193	\$1,144,869,849
40-59 years old	Female	19,735,062	20,527,098	40,262,160	\$2,408,505,972
40-59 years old	Male	15,231,183	18,739,340	33,970,523	\$1,948,484,333
60+ years old	Female	91,916,609	17,524,653	109,441,262	\$5,423,906,556
60+ years old	Male	75,463,424	20,258,684	95,722,108	\$5,714,336,503

Approximately 0.4% of all prescriptions are excluded due to patient gender being 'X' or unknown patient demographic details.

Reported gender in the PBS Online Claims Data is sourced from Services Australia.

Department of Health, Disability and Ageing does not have access to Medicare personal records.

Table 6(d): PBS prescriptions dispensed in a RACF, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

State	PBS Prescriptions	Percentage
NSW	4,909,846	34.0%
VIC	3,838,101	26.6%
QLD	2,868,070	19.8%
SA	1,189,058	8.2%
WA	1,126,062	7.8%
TAS	291,903	2.0%
NT	22,092	0.2%
ACT	204,695	1.4%
Australia	14,449,827	100.0%

Table 6(e): Top 10 PBS Drugs (by Active Ingredient) by Highest Government Cost, dispensed in a RACF, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution*	Total Cost**
1	MOLNUPIRAVIR	36,111	\$39,560,744	\$250,010	\$39,810,754
2	APIXABAN	343,147	\$22,128,973	\$2,191,535	\$24,320,508
3	DENOSUMAB	87,671	\$21,739,246	\$633,041	\$22,372,286
4	LEVODOPA + CARBIDOPA	66,792	\$14,145,089	\$393,082	\$14,538,171
5	BUPRENORPHINE	523,237	\$13,979,364	\$2,246,160	\$16,225,524
6	NIRMATRELVIR (&) RITONAVIR	9,467	\$10,485,988	\$72,652	\$10,558,640
7	OXYCODONE + NALOXONE	290,527	\$9,342,957	\$1,183,318	\$10,526,275
8	PANTOPRAZOLE	669,025	\$8,498,482	\$2,703,813	\$11,202,296
9	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	477,395	\$7,051,167	\$1,752,400	\$8,803,567
10	PARACETAMOL	497,309	\$6,735,753	\$1,650,045	\$8,385,798

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

Table 6(f): Top 10 PBS Drugs (by Active Ingredient) by Highest Prescriptions, dispensed in a RACF, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution*	Total Cost**
1	PANTOPRAZOLE	669,025	\$8,498,482	\$2,703,813	\$11,202,296
2	BUPRENORPHINE	523,237	\$13,979,364	\$2,246,160	\$16,225,524
3	PARACETAMOL	497,309	\$6,735,753	\$1,650,045	\$8,385,798
4	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	477,395	\$7,051,167	\$1,752,400	\$8,803,567
5	ATORVASTATIN	394,533	\$4,700,818	\$1,453,421	\$6,154,239
6	MIRTAZAPINE	389,473	\$4,642,599	\$1,390,481	\$6,033,080
7	APIXABAN	343,147	\$22,128,973	\$2,191,535	\$24,320,508
8	FUROSEMIDE	306,842	\$3,796,089	\$1,065,608	\$4,861,697
9	ROSUVASTATIN	296,706	\$3,586,118	\$1,077,808	\$4,663,925
10	OXYCODONE + NALOXONE	290,527	\$9,342,957	\$1,183,318	\$10,526,275

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

Table 7: Top 50 ATC Level 2 Drug Groups by Highest Total Prescription Volume, 2024-25

Section 85 and Section 100, including Prescriber Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	N06	PSYCHOANALEPTICS	23,440,953	17,375,377	40,816,330
2	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	22,071,773	14,213,377	36,285,150
3	C10	LIPID MODIFYING AGENTS	23,379,330	12,827,712	36,207,042
4	A02	DRUGS FOR ACID RELATED DISORDERS	16,298,084	7,601,032	23,899,116
5	J01	ANTIBACTERIALS FOR SYSTEMIC USE	10,039,231	12,518,326	22,557,557
6	A10	DRUGS USED IN DIABETES	18,783,193	2,900,925	21,684,118
7	N02	ANALGESICS	15,360,820	5,243,465	20,604,285
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,661,234	1,384,862	13,046,096
9	B01	ANTITHROMBOTIC AGENTS	10,181,458	816,528	10,997,986
10	C07	BETA BLOCKING AGENTS	6,686,999	2,515,690	9,202,689
11	S01	OPHTHALMOLOGICALS	7,540,245	1,513,021	9,053,266
12	N05	PSYCHOLEPTICS	6,740,968	1,914,798	8,655,766
13	C08	CALCIUM CHANNEL BLOCKERS	5,963,162	2,650,142	8,613,304
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,260,059	3,234,596	6,494,655
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	3,163,708	2,541,333	5,705,041
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,142,008	2,147,595	4,289,603
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,438,444	1,797,321	4,235,765
18	C01	CARDIAC THERAPY	2,893,699	690,932	3,584,631
19	N03	ANTIPILEPTICS	2,693,229	727,979	3,421,208
20	C03	DIURETICS	2,581,536	648,318	3,229,854
21	G04	UROLOGICALS	2,440,194	488,676	2,928,870
22	L04	IMMUNOSUPPRESSANTS	2,572,251	141,704	2,713,955
23	C02	ANTIHYPERTENSIVES	1,702,957	690,639	2,393,596
24	M05	DRUGS FOR TREATMENT OF BONE DISEASES	2,262,715	117,254	2,379,969
25	L01	ANTINEOPLASTIC AGENTS	2,256,567	100,571	2,357,138
26	H03	THYROID THERAPY	1,326,606	1,021,095	2,347,701
27	M04	ANTIGOUT PREPARATIONS	1,335,131	968,742	2,303,873
28	J05	ANTIVIRALS FOR SYSTEMIC USE	1,279,673	697,273	1,976,946
29	N04	ANTI-PARKINSON DRUGS	1,602,677	200,886	1,803,563
30	A06	DRUGS FOR CONSTIPATION	1,288,565	105,377	1,393,942
31	A04	ANTIEMETICS AND ANTINAUSEANTS	871,989	503,862	1,375,851
32	B03	ANTIANEMIC PREPARATIONS	1,223,920	137,121	1,361,041
33	N07	OTHER NERVOUS SYSTEM DRUGS	1,299,634	30,653	1,330,287
34	L02	ENDOCRINE THERAPY	937,337	281,793	1,219,130
35	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	745,360	352,657	1,098,017
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	933,093	44,816	977,909
37	S02	OTOLOGICALS	480,411	474,296	954,707
38	D10	ANTI-ACNE PREPARATIONS	415,347	94,014	509,361
39	D11	OTHER DERMATOLOGICAL PREPARATIONS	422,994	69,968	492,962
40	M03	MUSCLE RELAXANTS	371,526	66,648	438,174
41	A12	MINERAL SUPPLEMENTS	376,252	52,084	428,336
42	D05	ANTIPSORIATICS	318,327	8,724	327,051
43	G02	OTHER GYNECOLOGICALS	222,438	4,492	226,930
44	B02	ANTIHEMORRHAGICS	186,453	36,141	222,594
45	A09	DIGESTIVES, INCL. ENZYMES	219,413	224	219,637
46	A11	VITAMINS	167,740	38,234	205,974
47	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	193,493	70	193,563
48	L03	IMMUNOSTIMULANTS	172,294	1,052	173,346
49	A01	STOMATOLOGICAL PREPARATIONS	82,064	47,549	129,613
50	V03	ALL OTHER THERAPEUTIC PRODUCTS	122,825	5,528	128,353

The Anatomical Therapeutic Chemical (ATC) is an international classification for medicines developed by the World Health Organisation and used in the PBS Schedule and referred to as Body Systems.

<https://www.pbs.gov.au/browse/body-system>

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24 and 2024-25
Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution*			
	2023-24	2024-25	Prescriptions Change	Percentage Change	2023-24	2024-25	Gov Cost Change	Percentage Change	2023-24	2024-25	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	39,332,966	39,844,685	511,719	1.3%	\$1,484,859,555	\$1,606,767,889	\$121,908,335	8.2%	\$305,465,913	\$317,933,478	\$12,467,565	4.1%
BLOOD AND BLOOD FORMING ORGANS	11,829,888	11,594,368	-235,520	-2.0%	\$987,779,145	\$911,773,330	-\$76,005,815	-7.7%	\$116,150,699	\$116,993,294	\$842,595	0.7%
CARDIOVASCULAR SYSTEM	68,815,497	65,280,279	-3,535,218	-5.1%	\$1,253,458,936	\$1,324,812,796	\$71,353,861	5.7%	\$348,188,573	\$347,289,510	-\$899,063	-0.3%
DERMATOLOGICALS	3,565,419	3,680,811	115,392	3.2%	\$443,306,412	\$521,599,426	\$78,293,015	17.7%	\$42,630,867	\$45,910,333	\$3,279,466	7.7%
GENITO URINARY SYSTEM AND SEX HORMONES	5,133,757	5,826,340	692,583	13.5%	\$314,788,057	\$359,373,020	\$44,584,963	14.2%	\$51,544,969	\$72,410,352	\$20,865,383	40.5%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,758,421	3,768,532	10,111	0.3%	\$162,670,601	\$172,099,168	\$9,428,567	5.8%	\$24,816,793	\$25,876,786	\$1,059,992	4.3%
ANTIINFECTIVES FOR SYSTEMIC USE	11,518,091	11,436,982	-81,109	-0.7%	\$1,486,095,033	\$1,150,246,607	-\$335,848,427	-22.6%	\$81,796,261	\$77,111,151	-\$4,685,110	-5.7%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	5,653,522	5,938,449	284,927	5.0%	\$7,225,333,491	\$8,102,886,568	\$877,553,078	12.1%	\$77,247,664	\$84,700,679	\$7,453,015	9.6%
MUSCULO-SKELETAL SYSTEM	7,213,674	7,231,502	17,828	0.2%	\$664,106,735	\$735,121,126	\$71,014,391	10.7%	\$49,229,718	\$51,302,339	\$2,072,620	4.2%
NERVOUS SYSTEM	49,237,668	51,160,702	1,923,034	3.9%	\$1,588,557,091	\$1,893,804,078	\$305,246,987	19.2%	\$354,377,018	\$392,343,229	\$37,966,211	10.7%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	93,889	154,217	60,328	64.3%	\$4,621,326	\$6,686,931	\$2,065,606	44.7%	\$1,064,424	\$2,031,086	\$966,662	90.8%
RESPIRATORY SYSTEM	11,834,804	11,753,577	-81,227	-0.7%	\$1,286,666,329	\$1,384,846,124	\$98,179,795	7.6%	\$127,919,945	\$130,451,687	\$2,531,742	2.0%
SENSORY ORGANS	8,276,311	8,033,440	-242,871	-2.9%	\$787,674,620	\$828,293,039	\$40,618,419	5.2%	\$47,699,272	\$48,055,185	\$355,913	0.7%
VARIOUS	186,959	187,316	357	0.2%	\$57,572,879	\$58,907,516	\$1,334,637	2.3%	\$2,572,962	\$2,578,480	\$5,518	0.2%
UNLESS OTHERWISE CLASSIFIED	82,842	74,320	-8,522	-10.3%	\$3,376,058	\$3,521,106	\$145,048	4.3%	\$572,034	\$526,024	-\$46,010	-8.0%
TOTAL	226,533,708	225,965,520	-568,188	-0.3%	\$17,750,866,267	\$19,060,738,727	\$1,309,872,460	7.4%	\$1,631,277,111	\$1,715,513,611	\$84,236,500	5.2%

ATC Group Level 1	Total Cost**				Average Price***			
	2023-24	2024-25	Total Cost Change	Percentage Change	2023-24	2024-25	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$1,790,325,468	\$1,924,701,368	\$134,375,900	7.5%	\$45.52	\$48.31	\$2.79	6.1%
BLOOD AND BLOOD FORMING ORGANS	\$1,103,929,844	\$1,028,766,624	-\$75,163,220	-6.8%	\$93.32	\$88.73	-\$4.59	-4.9%
CARDIOVASCULAR SYSTEM	\$1,601,647,509	\$1,672,102,306	\$70,454,798	4.4%	\$23.27	\$25.61	\$2.34	10.1%
DERMATOLOGICALS	\$485,937,279	\$567,509,759	\$81,572,480	16.8%	\$136.29	\$154.18	\$17.89	13.1%
GENITO URINARY SYSTEM AND SEX HORMONES	\$366,333,026	\$431,783,371	\$65,450,346	17.9%	\$71.36	\$74.11	\$2.75	3.9%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$187,487,394	\$197,975,954	\$10,488,559	5.6%	\$49.88	\$52.53	\$2.65	5.3%
ANTIINFECTIVES FOR SYSTEMIC USE	\$1,567,891,294	\$1,227,357,757	-\$340,533,537	-21.7%	\$136.12	\$107.31	-\$28.81	-21.2%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$7,302,581,154	\$8,187,587,247	\$885,006,093	12.1%	\$1,291.69	\$1,378.74	\$87.05	6.7%
MUSCULO-SKELETAL SYSTEM	\$713,336,453	\$786,423,465	\$73,087,012	10.2%	\$98.89	\$108.75	\$9.86	10.0%
NERVOUS SYSTEM	\$1,942,934,108	\$2,286,147,307	\$343,213,198	17.7%	\$39.46	\$44.69	\$5.23	13.3%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$5,685,749	\$8,718,017	\$3,032,268	53.3%	\$60.56	\$56.53	-\$4.03	-6.7%
RESPIRATORY SYSTEM	\$1,414,586,274	\$1,515,297,811	\$100,711,537	7.1%	\$119.53	\$128.92	\$9.39	7.9%
SENSORY ORGANS	\$835,373,892	\$876,348,224	\$40,974,332	4.9%	\$100.94	\$109.09	\$8.15	8.1%
VARIOUS	\$60,145,841	\$61,485,996	\$1,340,156	2.2%	\$321.71	\$328.25	\$6.54	2.0%
UNLESS OTHERWISE CLASSIFIED	\$3,948,092	\$4,047,131	\$99,038	2.5%	\$47.66	\$54.46	\$6.80	14.3%
TOTAL	\$19,382,143,378	\$20,776,252,338	\$1,394,108,960	7.2%	\$85.56	\$91.94	\$6.38	7.5%


* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Figure 7(a): Percentages of subsidised prescriptions for ATC main groups, 2024-25

Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions



ATC A: ALIMENTARY TRACT AND METABOLISM

ATC C: CARDIOVASCULAR SYSTEM

ATC G: GENITO URINARY SYSTEM AND SEX HORMONES

ATC J: ANTIINFECTIVES FOR SYSTEMIC USE

ATC M: MUSCULO-SKELETAL SYSTEM

ATC R: RESPIRATORY SYSTEM

Others: Unless otherwise classified, **ATC - P:** ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS, and **ATC V:** VARIOUS

ATC B: BLOOD AND BLOOD FORMING ORGANS

ATC D: DERMATOLOGICALS

ATC H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

ATC L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS


ATC N: NERVOUS SYSTEM

ATC S: SENSORY ORGANS

The Source of the data is from Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24 and 2024-25

Figure 7(b): Percentages of Government Cost for ATC main groups, 2024-25

Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions



ATC A: ALIMENTARY TRACT AND METABOLISM

ATC C: CARDIOVASCULAR SYSTEM

ATC G: GENITO URINARY SYSTEM AND SEX HORMONES

ATC J: ANTIINFECTIVES FOR SYSTEMIC USE

ATC M: MUSCULO-SKELETAL SYSTEM

ATC R: RESPIRATORY SYSTEM

Others: Unless otherwise classified, **ATC - P:** ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS, and **ATC V:** VARIOUS

ATC B: BLOOD AND BLOOD FORMING ORGANS

ATC D: DERMATOLOGICALS

ATC H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

ATC L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

ATC N: NERVOUS SYSTEM

ATC S: SENSORY ORGANS

The Source of the data is from Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24 and 2024-25

Table 9(a): Top 35 Drugs by Highest Change to Government Cost, 2023-24 and 2024-25
 Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Rank	Drug Name	2023-24					2024-25					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***		
1	TAFAMIDIS	387	\$3,873,598	\$4,318	\$3,877,916	\$10,020	13,922	\$139,381,650	\$135,068	\$139,516,717	\$10,021	\$135,508,052	3,498.25%
2	DUPILUMAB	213,310	\$366,167,453	\$4,994,676	\$371,162,129	\$1,740	281,099	\$482,137,569	\$6,645,806	\$488,783,375	\$1,739	\$115,970,116	31.67%
3	PEMBROLIZUMAB	66,559	\$566,973,633	\$299,366	\$567,272,999	\$8,523	78,956	\$669,833,956	\$348,572	\$670,182,528	\$8,488	\$102,860,323	18.14%
4	DAROLUTAMIDE	16,825	\$58,924,105	\$229,075	\$59,153,180	\$3,516	40,789	\$142,784,560	\$564,432	\$143,348,991	\$3,514	\$83,860,455	142.32%
5	USTEKINUMAB	60,123	\$435,444,883	\$1,403,987	\$436,848,869	\$7,266	73,601	\$517,329,069	\$1,750,475	\$519,079,544	\$7,053	\$81,884,186	18.80%
6	UPADACITINIB	150,662	\$211,177,228	\$3,162,344	\$214,339,572	\$1,423	195,775	\$284,746,347	\$4,279,293	\$289,025,640	\$1,476	\$73,569,118	34.84%
7	NIVOLUMAB + RELATIMAB	760	\$13,811,379	\$12,849	\$13,824,228	\$18,190	4,440	\$81,029,526	\$48,542	\$81,078,068	\$18,261	\$67,218,147	486.69%
8	TRASTUZUMAB DERUXTECAN	3,359	\$34,018,258	\$17,127	\$34,035,384	\$10,133	9,983	\$98,418,216	\$42,397	\$98,460,613	\$9,863	\$64,399,959	189.31%
9	ABEMACICLIB	11,001	\$46,313,757	\$185,851	\$46,499,608	\$4,227	26,049	\$108,262,393	\$532,032	\$108,794,425	\$4,177	\$61,948,636	133.76%
10	UPANUBRUTINIB	9,625	\$76,824,608	\$118,419	\$76,943,028	\$7,994	16,586	\$130,157,390	\$202,758	\$130,360,148	\$7,860	\$53,332,782	69.42%
11	SEMAGLUTIDE	2,397,325	\$284,610,195	\$36,467,446	\$321,077,640	\$134	2,819,530	\$335,781,950	\$43,607,035	\$379,388,985	\$135	\$51,171,755	17.98%
12	AFLIBERCEPT	423,425	\$414,049,215	\$5,619,687	\$419,668,902	\$991	472,372	\$463,999,619	\$6,259,477	\$470,259,095	\$996	\$49,950,404	12.06%
13	ELEXACFTOR + TEZACFTOR + IVACFTOR (&) IVACFTOR	26,587	\$568,268,710	\$367,331	\$568,636,041	\$21,388	29,267	\$617,774,730	\$391,230	\$618,165,960	\$21,122	\$49,506,020	8.71%
14	BIMEKIZUMAB	2,655	\$9,020,926	\$62,236	\$9,083,163	\$3,421	16,794	\$57,048,153	\$385,406	\$57,433,560	\$3,420	\$48,027,227	532.40%
15	LISDEXAMFETAMINE	1,542,830	\$119,682,055	\$36,433,081	\$156,115,136	\$101	2,196,214	\$167,623,993	\$54,172,816	\$221,796,809	\$101	\$47,941,939	40.06%
16	DURVALUMAB	10,752	\$113,444,508	\$56,484	\$113,500,992	\$10,556	14,875	\$160,804,376	\$75,981	\$160,880,357	\$10,815	\$47,359,869	41.75%
17	BUPRENORPHINE	1,381,217	\$94,632,954	\$10,235,881	\$104,868,835	\$76	1,554,221	\$131,907,283	\$12,592,594	\$144,499,877	\$93	\$37,274,329	39.39%
18	INCLISIRAN	2,186	\$4,000,833	\$41,656	\$4,042,489	\$1,849	22,423	\$41,048,341	\$414,441	\$41,462,782	\$1,849	\$37,047,509	925.99%
19	OFATUMUMAB	26,983	\$63,517,231	\$618,205	\$64,135,435	\$2,377	39,919	\$92,127,038	\$937,973	\$93,065,012	\$2,331	\$28,609,807	45.04%
20	DARATUMUMAB	25,584	\$182,912,371	\$352,816	\$183,265,187	\$7,163	29,631	\$211,485,612	\$421,975	\$211,907,587	\$7,152	\$28,573,241	15.62%
21	RAVULIZUMAB	1,204	\$73,161,317	\$30,827	\$73,192,144	\$60,791	1,612	\$101,141,090	\$41,932	\$101,183,022	\$62,769	\$27,979,773	38.24%
22	RISANKIZUMAB	18,109	\$97,364,557	\$438,874	\$97,803,430	\$5,401	23,115	\$122,746,156	\$571,251	\$123,317,407	\$5,335	\$25,381,599	26.07%
23	VEDOLIZUMAB	63,369	\$153,347,178	\$1,603,935	\$154,951,113	\$2,445	75,266	\$177,155,593	\$1,906,742	\$179,062,335	\$2,379	\$23,808,415	15.53%
24	DEUCRAVACITINIB	11,055	\$13,654,725	\$265,735	\$13,920,460	\$1,259	29,952	\$37,014,964	\$704,584	\$37,719,548	\$1,259	\$23,360,239	171.08%
25	MEPOLIZUMAB	38,982	\$61,680,178	\$730,868	\$62,411,047	\$1,601	52,246	\$82,677,980	\$1,021,628	\$83,699,608	\$1,602	\$20,997,802	34.04%
26	EMPAGLIFLOZIN	1,751,252	\$85,712,304	\$21,562,135	\$107,274,439	\$61	2,034,950	\$105,911,173	\$24,352,494	\$130,263,667	\$64	\$20,198,868	23.57%
27	CEMPIPLIMAB	14,418	\$107,705,282	\$42,711	\$107,747,992	\$7,473	17,128	\$127,898,582	\$51,818	\$127,950,400	\$7,470	\$20,193,300	18.75%
28	OSIMERTINIB	20,841	\$163,459,948	\$335,324	\$163,795,272	\$7,859	24,290	\$183,410,125	\$392,424	\$183,802,550	\$7,567	\$19,950,177	12.20%
29	DAPAGLIFLOZIN	1,525,520	\$69,334,982	\$18,238,050	\$87,573,032	\$57	1,915,738	\$87,333,780	\$22,427,280	\$109,761,060	\$57	\$17,998,797	25.96%
30	FREMANEZUMAB	113,583	\$61,059,353	\$2,536,864	\$63,596,217	\$560	145,999	\$78,514,128	\$3,300,493	\$81,814,621	\$560	\$17,454,775	28.59%
31	OLAPARIB	6,243	\$40,059,469	\$107,257	\$40,166,726	\$6,434	8,949	\$57,459,915	\$165,319	\$57,625,234	\$6,439	\$17,400,446	43.44%
32	EVOLOCUMAB	131,334	\$46,415,018	\$2,297,865	\$48,712,883	\$371	179,217	\$63,272,794	\$3,127,463	\$66,400,256	\$371	\$16,857,776	36.32%
33	BLINATUMOMAB	244	\$17,765,796	\$3,369	\$17,769,165	\$72,824	479	\$34,489,661	\$7,524	\$34,497,185	\$72,019	\$16,723,865	94.14%
34	MAVACAMTEN	297	\$682,882	\$6,341	\$689,223	\$2,321	7,369	\$16,968,865	\$136,640	\$17,105,504	\$2,321	\$16,285,982	2,384.89%
35	DENOSUMAB	1,154,889	\$291,451,304	\$11,559,129	\$303,010,434	\$262	1,221,393	\$307,397,315	\$12,395,725	\$319,793,039	\$262	\$15,946,010	5.47%

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 9(b): Top 35 Drugs by Highest Change to Subsidised Script Volume, 2023-24 and 2024-25
 Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Rank	Drug Name	2023-24					2024-25					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***		
1	LISDEXAMFETAMINE	1,542,830	\$119,682,055	\$36,433,081	\$156,115,136	\$101.19	2,196,214	\$167,623,993	\$54,172,816	\$221,796,809	\$100.99	653,384	42.35%
2	SEMAGLUTIDE	2,397,325	\$284,610,195	\$36,467,446	\$321,077,640	\$133.93	2,819,530	\$335,781,950	\$43,607,035	\$379,388,985	\$134.56	422,205	17.61%
3	DAPAGLIFLOZIN	1,525,520	\$69,334,982	\$18,238,050	\$87,573,032	\$57.41	1,915,738	\$87,333,780	\$22,427,280	\$109,761,060	\$57.29	390,218	25.58%
4	EZETIMIBE	1,280,431	\$19,618,349	\$5,608,449	\$25,226,798	\$19.70	1,662,752	\$25,636,520	\$7,630,675	\$33,267,195	\$20.01	382,321	29.86%
5	EMPAGLIFLOZIN	1,751,252	\$85,712,304	\$21,562,135	\$107,274,439	\$61.26	2,034,950	\$105,911,173	\$24,352,494	\$130,263,667	\$64.01	283,698	16.20%
6	METHYLPHENIDATE	1,438,508	\$49,526,005	\$26,251,058	\$75,777,063	\$52.68	1,688,440	\$56,032,037	\$33,025,854	\$89,057,891	\$52.75	249,932	17.37%
7	APIXABAN	4,043,784	\$336,157,261	\$40,194,578	\$376,351,838	\$93.07	4,235,206	\$274,855,457	\$42,903,353	\$317,758,810	\$75.03	191,422	4.73%
8	PANTOPRAZOLE	7,206,717	\$83,600,846	\$33,298,033	\$116,898,879	\$16.22	7,389,809	\$88,919,819	\$34,719,994	\$123,639,813	\$16.73	183,092	2.54%
9	BECLOMETASONE + FORMOTEROL + GLYCOPYRRONIUM	283,150	\$20,118,342	\$2,673,726	\$22,792,068	\$80.49	463,067	\$32,328,331	\$4,656,544	\$36,984,875	\$79.87	179,917	63.54%
10	ESTRADIOL	681,530	\$14,594,803	\$4,118,802	\$18,713,605	\$27.46	860,696	\$18,837,486	\$9,892,597	\$28,730,083	\$33.38	179,166	26.29%
11	BUPRENORPHINE	1,381,217	\$94,632,954	\$10,235,881	\$104,868,835	\$75.92	1,554,221	\$131,907,283	\$12,592,594	\$144,499,877	\$92.97	173,004	12.53%
12	HYALURONATE SODIUM	837,802	\$24,445,301	\$4,464,666	\$28,909,967	\$34.51	995,935	\$30,481,571	\$5,319,868	\$35,801,440	\$35.95	158,133	18.87%
13	GUANFACINE	521,424	\$34,245,276	\$8,574,777	\$42,820,053	\$82.12	641,700	\$31,501,650	\$11,063,316	\$42,564,965	\$66.33	120,276	23.07%
14	DOXYCYCLINE	1,161,997	\$14,190,680	\$5,713,200	\$19,903,881	\$17.13	1,279,915	\$15,813,213	\$6,657,703	\$22,470,916	\$17.56	117,918	10.15%
15	PROGESTERONE	64,722	\$5,962,602	\$1,882,802	\$7,845,404	\$121.22	180,098	\$9,134,437	\$5,200,277	\$14,334,714	\$79.59	115,376	178.26%
16	NIZATIDINE	373,141	\$7,168,931	\$1,572,945	\$8,741,875	\$23.43	479,081	\$9,478,482	\$2,275,120	\$11,753,602	\$24.53	105,940	28.39%
17	ESTRIOL	369,145	\$7,136,621	\$2,127,596	\$9,264,217	\$25.10	471,224	\$8,868,955	\$4,581,447	\$13,450,402	\$28.54	102,079	27.65%
18	SERTRALINE	2,516,154	\$28,469,802	\$13,461,899	\$41,931,701	\$16.66	2,612,578	\$30,099,142	\$14,212,209	\$44,311,351	\$16.96	96,424	3.83%
19	OXYCODONE	1,941,128	\$48,017,268	\$10,483,635	\$58,500,903	\$30.14	2,035,208	\$51,080,493	\$11,184,206	\$62,264,700	\$30.59	94,080	4.85%
20	PARACETAMOL	1,811,800	\$29,118,198	\$6,166,868	\$35,285,067	\$19.48	1,902,047	\$31,210,185	\$6,590,263	\$37,800,448	\$19.87	90,247	4.98%
21	ESCITALOPRAM	2,481,771	\$27,407,336	\$13,474,186	\$40,881,522	\$16.47	2,571,161	\$29,042,172	\$14,218,459	\$43,260,631	\$16.83	89,390	3.60%
22	DEXAMFETAMINE	457,806	\$8,276,124	\$8,227,993	\$16,504,117	\$36.05	540,024	\$9,893,241	\$9,859,483	\$19,752,724	\$36.58	82,218	17.96%
23	TAPENTADOL	1,217,075	\$42,191,485	\$9,599,062	\$51,790,547	\$42.55	1,293,517	\$44,965,717	\$10,183,736	\$55,149,453	\$42.64	76,442	6.28%
24	MIRTAZAPINE	2,429,672	\$30,539,052	\$11,085,162	\$41,624,214	\$17.13	2,505,111	\$32,294,762	\$11,530,932	\$43,825,695	\$17.49	75,439	3.10%
25	CEFALEXIN	2,328,684	\$26,116,634	\$12,531,282	\$38,647,916	\$16.60	2,397,681	\$27,869,908	\$13,161,829	\$41,031,737	\$17.11	68,997	2.96%
26	FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL	866,759	\$69,998,969	\$8,094,006	\$78,092,975	\$90.10	935,637	\$77,591,042	\$9,134,190	\$86,725,232	\$92.69	68,878	7.95%
27	DUPILUMAB	213,310	\$366,167,453	\$4,994,676	\$371,162,129	\$1,740.01	281,099	\$482,137,569	\$6,645,806	\$488,783,375	\$1,738.83	67,789	31.78%
28	DENOSUMAB	1,154,889	\$291,451,304	\$11,559,129	\$303,010,434	\$262.37	1,221,393	\$307,397,315	\$12,395,725	\$319,793,039	\$261.83	66,504	5.76%
29	AMOXICILLIN + CLAVULANIC ACID	1,391,845	\$16,776,924	\$7,627,402	\$24,404,325	\$17.53	1,455,625	\$18,060,172	\$8,116,228	\$26,176,399	\$17.98	63,780	4.58%
30	CLONIDINE	351,324	\$7,287,028	\$2,130,739	\$9,417,768	\$26.81	411,849	\$8,543,390	\$2,954,094	\$11,497,484	\$27.92	60,525	17.23%
31	SACUBITRIL + VALSARTAN	765,460	\$144,714,233	\$8,500,302	\$153,214,536	\$200.16	824,477	\$145,846,550	\$9,307,214	\$155,153,764	\$188.18	59,017	7.71%
32	POLYETHYLENE GLYCOL-400 + PROPYLENE GLYCOL	423,476	\$6,721,693	\$1,597,257	\$8,318,949	\$19.64	478,681	\$8,522,650	\$1,949,265	\$10,471,915	\$21.88	55,205	13.04%
33	LIQUID PARAFFIN + GLYCEROL + TYLOXAPOL + POLOXAMER-188 + TROMETAMOL HYDROCHLORIDE + TROMETAMOL + CETALKONIUM CHLORIDE	89,711	\$2,799,530	\$581,449	\$3,380,979	\$37.69	144,547	\$4,507,537	\$903,420	\$5,410,957	\$37.43	54,836	61.13%
34	AFLIBERCEPT	423,425	\$414,049,215	\$5,619,687	\$419,668,902	\$991.13	472,372	\$463,999,619	\$6,259,477	\$470,259,095	\$995.53	48,947	11.56%
35	EVOLOCUMAB	131,334	\$46,415,018	\$2,297,865	\$48,712,883	\$370.91	179,217	\$63,272,794	\$3,127,463	\$66,400,256	\$370.50	47,883	36.46%

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 9(c): Top 5 PBS Drugs by Fastest Prescription Growth, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Fastest growing ATC4 categories	Increase*	2024-25 Prescriptions
N06BA - Centrally acting sympathomimetics	1,204,106	5,407,659
A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors	673,994	3,950,969
C10AX - Other lipid modifying agents	652,966	2,683,893
A10BJ - Glucagon-like peptide-1 (GLP-1) analogues	380,394	3,165,461
R03AL - Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	155,607	2,164,980
Fastest growing Drugs		
LISDEXAMFETAMINE	653,396	2,196,304
EZETIMIBE	591,874	2,476,155
SEMAGLUTIDE	411,663	2,819,530
DAPAGLIFLOZIN	390,275	1,915,899
METHYLPHENIDATE	297,208	2,029,344
Fastest growing Items		
14163K (SEMAGLUTIDE)	1,379,294	1,393,861
13586C (ROSUVASTATIN)	816,026	1,350,696
13588E (ROSUVASTATIN)	546,007	885,105
13406N (ROSUVASTATIN)	512,747	860,742
13468W (ATORVASTATIN)	455,458	732,888

* Increase in number of prescriptions compared to previous financial year.

Table 9(d): Top 5 PBS Drugs by Fastest Government Cost Growth, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Fastest growing ATC4 categories	Increase*	2024-25 Government cost
L04AC - Interleukin inhibitors	\$157,170,675	\$1,128,583,887
L01FF - PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors	\$156,767,612	\$1,586,765,649
N07XX - Other nervous system drugs	\$135,240,721	\$158,330,283
L02BB - Anti-androgens	\$102,974,793	\$355,708,682
L04AF - Janus-associated kinase (JAK) inhibitors	\$86,787,329	\$404,017,275
Fastest growing Drugs		
TAFAMIDIS	\$135,508,052	\$139,381,650
DUPIUMAB	\$115,970,116	\$482,137,569
PEMBROLIZUMAB	\$102,860,323	\$669,833,956
DAROLUTAMIDE	\$83,860,455	\$142,784,560
USTEKINUMAB	\$81,884,186	\$517,329,069
Fastest growing Items		
14163K (SEMAGLUTIDE)	\$1,379,294	\$1,393,861
13586C (ROSUVASTATIN)	\$816,026	\$1,350,696
13588E (ROSUVASTATIN)	\$546,007	\$885,105
13406N (ROSUVASTATIN)	\$512,747	\$860,742
13468W (ATORVASTATIN)	\$455,458	\$732,888


* Increase in number of prescriptions compared to previous financial year.

Table 10(a): PBS Generic Prescriptions per ATC level 1, 2024-25

Section 85 and Section 100, including under co-payment prescriptions and Prescriber Bag, excluding EFC items

ATC Level 1 Group	Total Prescriptions	Total Prescriptions Generic Percentage*	Total Expenditure	Total Expenditure Generic Percentage
ATC - A: ALIMENTARY TRACT AND METABOLISM	51,250,518	64.3%	\$1,603,577,172	26.6%
ATC - B: BLOOD AND BLOOD FORMING ORGANS	12,583,510	31.7%	\$911,751,511	9.5%
ATC - C: CARDIOVASCULAR SYSTEM	99,514,037	82.7%	\$1,324,769,359	57.1%
ATC - D: DERMATOLOGICALS	5,709,232	76.9%	\$521,431,726	12.1%
ATC - G: GENITO URINARY SYSTEM AND SEX HORMONES	8,860,737	62.3%	\$359,369,724	27.9%
ATC - H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	6,937,858	91.4%	\$172,092,903	47.2%
ATC - J: ANTIINFECTIVES FOR SYSTEMIC USE	24,671,352	91.3%	\$1,150,103,998	14.4%
ATC - L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	5,028,593	45.2%	\$5,585,340,471	6.8%
ATC - M: MUSCULO-SKELETAL SYSTEM	11,618,388	67.2%	\$735,115,473	8.5%
ATC - N: NERVOUS SYSTEM	76,492,675	73.9%	\$1,890,160,820	35.1%
ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	176,073	10.5%	\$6,686,914	14.4%
ATC - R: RESPIRATORY SYSTEM	13,131,978	45.5%	\$1,384,417,713	10.0%
ATC - S: SENSORY ORGANS	10,037,832	22.0%	\$828,284,953	2.9%
ATC - V: VARIOUS	134,589	47.8%	\$29,236,370	31.4%

* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for each ATC classification

**Table 10(b): PBS Generic Prescriptions Percentage Share by ATC level 1, 2024-25**

Section 85 and Section 100, including under co-payment prescriptions and Prescriber Bag, excluding EFC items

ATC Level 1 Group	Total Prescriptions Generic Percentage*	Total Expenditure Generic Percentage*
ATC - A: ALIMENTARY TRACT AND METABOLISM	14.1%	14.4%
ATC - B: BLOOD AND BLOOD FORMING ORGANS	1.7%	2.9%
ATC - C: CARDIOVASCULAR SYSTEM	35.4%	25.6%
ATC - D: DERMATOLOGICALS	1.9%	2.1%
ATC - G: GENITO URINARY SYSTEM AND SEX HORMONES	2.4%	3.4%
ATC - H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	2.7%	2.8%
ATC - J: ANTIINFECTIVES FOR SYSTEMIC USE	9.7%	5.6%
ATC - L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1.0%	12.8%
ATC - M: MUSCULO-SKELETAL SYSTEM	3.4%	2.1%
ATC - N: NERVOUS SYSTEM	24.3%	22.4%
ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	< 0.1%	< 0.1%
ATC - R: RESPIRATORY SYSTEM	2.6%	4.7%
ATC - S: SENSORY ORGANS	1.0%	0.8%
ATC - V: VARIOUS	< 0.1%	0.3%
Total	100.0%	100.0%

* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for all ATCs

Tables 10(a) and 10(b) Excludes non-therapeutic products (ATC V04 diagnostic agents, V06 general nutrients and V07 all other non-therapeutic products)

Table 11: PBS Prescriptions and Government Cost by Formulary, 2024-25

Section 85 and Section 100, including under co-payment prescriptions and Prescriber Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Prescriptions Percentage	Government Cost	Patient Contribution	Total Cost Percentage
F1	32,771,423	2,498,626	35,270,049	10.7%	\$12,270,070,704	\$490,761,197	56.2%
F2	182,637,896	99,160,076	281,797,972	85.9%	\$4,884,367,876	\$2,996,276,030	34.7%
Combination Drugs ²	10,478,086	544,440	11,022,526	3.4%	\$1,902,609,334	\$141,381,685	9.0%
Other ³	78,115	12,602	90,717	0.0%	\$3,690,813	\$797,627	0.0%
Total	225,965,520	102,215,744	328,181,264	100.0%	\$19,060,738,727	\$3,629,216,538	100.0%

¹ The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2.

Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands.

Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply.

Allocation to F1 or F2 is determined by legislative instrument.

² Combination Drugs are not allocated to any formulary.

³ The category 'Other' includes extemporaneously prepared items.

Table 12(a): Top 20 Responsible Persons by Total Cost, 2024-25

Section 85 and Section 100, including Prescriber Bag and under co-payment prescriptions, excluding EFC items

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	JANSSEN-CILAG PTY LTD	1,472,018	154,808	1,626,826	\$1,351,514,812	\$21,834,144	\$1,373,348,956	\$1,196,971,934
2	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,916,180	1,606,109	7,522,289	\$1,092,293,437	\$66,480,097	\$1,158,773,533	\$961,013,024
3	ABBVIE PTY LTD	1,985,799	287,267	2,273,066	\$968,610,358	\$22,720,424	\$991,330,782	\$905,184,318
4	APOTEX PTY LTD	44,464,435	21,093,646	65,558,081	\$684,229,971	\$233,629,662	\$917,859,634	\$354,000,970
5	BAYER AUSTRALIA LTD	1,804,128	434,385	2,238,513	\$696,213,640	\$26,518,719	\$722,732,360	\$631,739,177
6	ASTRAZENECA PTY LTD	5,132,269	551,217	5,683,486	\$657,012,642	\$63,785,841	\$720,798,483	\$549,347,904
7	PFIZER AUSTRALIA PTY LTD	2,375,202	961,860	3,337,062	\$651,298,190	\$24,252,813	\$675,551,003	\$607,313,832
8	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,142,646	1,319,890	5,462,536	\$640,026,227	\$34,488,116	\$674,514,343	\$513,190,014
9	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.	31,772	-	31,772	\$667,542,249	\$425,301	\$667,967,550	\$399,896,916
10	SANDOZ PTY LTD	26,482,518	20,877,508	47,360,026	\$494,811,142	\$153,556,321	\$648,367,463	\$331,769,207
11	ALPHAPHARM PTY LTD	26,565,468	13,498,599	40,064,067	\$479,971,574	\$148,611,015	\$628,582,589	\$306,614,794
12	ROCHE PRODUCTS PTY LTD	742,112	51,635	793,747	\$604,028,880	\$7,561,040	\$611,589,919	\$481,645,477
13	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	4,308,635	477,912	4,786,547	\$490,471,402	\$77,388,839	\$567,860,241	\$415,287,244
14	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,981,674	247,796	4,229,470	\$502,049,059	\$57,963,668	\$560,012,728	\$469,233,137
15	AMGEN AUSTRALIA PTY LIMITED	1,548,482	n.p.	1,548,482	\$498,843,354	\$17,745,976	\$516,589,330	\$412,147,221
16	BOEHRINGER INGELHEIM PTY LTD	8,136,387	1,337,024	9,473,411	\$433,164,447	\$82,907,514	\$516,071,961	\$387,277,633
17	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,322,784	1,907	4,324,691	\$428,612,850	\$44,564,851	\$473,177,701	\$365,854,363
18	ARROW PHARMA PTY LTD	19,956,523	9,308,504	29,265,027	\$344,899,991	\$98,305,852	\$443,205,843	\$192,063,409
19	GLAXOSMITHKLINE AUSTRALIA PTY LTD	4,916,537	718,673	5,635,210	\$303,014,897	\$46,613,407	\$349,628,304	\$201,246,675
20	GILEAD SCIENCES PTY LIMITED	134,072	-	134,072	\$317,258,171	\$3,091,356	\$320,349,526	\$313,202,346

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

Small cells with counts less than 6 are suppressed, marked as n.p. (not published), and removed from the total.

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2024-25

Section 85 and Section 100, including Prescriber Bag and under co-payment prescriptions, excluding EFC items

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	APOTEX PTY LTD	44,464,435	21,093,646	65,558,081	\$684,229,971	\$233,629,662	\$917,859,634	\$354,000,970
2	ALPHAPHARM PTY LTD	26,565,468	13,498,599	40,064,067	\$479,971,574	\$148,611,015	\$628,582,589	\$306,614,794
3	SANDOZ PTY LTD	26,482,518	20,877,508	47,360,026	\$494,811,142	\$153,556,321	\$648,367,463	\$331,769,207
4	ARROW PHARMA PTY LTD	19,956,523	9,308,504	29,265,027	\$344,899,991	\$98,305,852	\$443,205,843	\$192,063,409
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	9,994,425	6,403,476	16,397,901	\$171,957,003	\$65,699,819	\$237,656,823	\$119,429,655
6	BOEHRINGER INGELHEIM PTY LTD	8,136,387	1,337,024	9,473,411	\$433,164,447	\$82,907,514	\$516,071,961	\$387,277,633
7	ARROTEX PHARMACEUTICALS PTY LTD	7,200,781	2,407,250	9,608,031	\$212,630,483	\$70,055,930	\$282,686,413	\$186,066,477
8	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,916,180	1,606,109	7,522,289	\$1,092,293,437	\$66,480,097	\$1,158,773,533	\$961,013,024
9	ASTRAZENECA PTY LTD	5,132,269	551,217	5,683,486	\$657,012,642	\$63,785,841	\$720,798,483	\$549,347,904
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	4,916,537	718,673	5,635,210	\$303,014,897	\$46,613,407	\$349,628,304	\$201,246,675
11	WAGNER PHARMACEUTICALS PTY LTD	4,893,767	8,805,175	13,698,942	\$57,129,654	\$35,435,499	\$92,565,152	\$59,663,360
12	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,322,784	1,907	4,324,691	\$428,612,850	\$44,564,851	\$473,177,701	\$365,854,363
13	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	4,308,635	477,912	4,786,547	\$490,471,402	\$77,388,839	\$567,860,241	\$415,287,244
14	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,142,646	1,319,890	5,462,536	\$640,026,227	\$34,488,116	\$674,514,343	\$513,190,014
15	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,981,674	247,796	4,229,470	\$502,049,059	\$57,963,668	\$560,012,728	\$469,233,137
16	MUNDIPHARMA PTY LIMITED	2,651,636	257,129	2,908,765	\$121,960,021	\$19,599,997	\$141,560,017	\$85,208,211
17	SERVIER LABORATORIES (AUST.) PTY. LTD.	2,624,140	1,854,133	4,478,273	\$45,579,012	\$14,572,237	\$60,151,250	\$32,122,367
18	PFIZER AUSTRALIA PTY LTD	2,375,202	961,860	3,337,062	\$651,298,190	\$24,252,813	\$675,551,003	\$607,313,832
19	SEQIRUS (AUSTRALIA) PTY LTD	2,333,075	259,212	2,592,287	\$229,758,372	\$25,738,869	\$255,497,242	\$199,863,066
20	VIATRIS PTY LTD	2,281,444	937,982	3,219,426	\$71,037,027	\$14,772,036	\$85,809,063	\$58,205,277

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2024-25

Section 85 and Section 100, including Prescriber Bag and under co-payment prescriptions, excluding EFC items

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	APOTEX PTY LTD	44,464,435	21,093,646	65,558,081	\$684,229,971	\$233,629,662	\$917,859,634	\$354,000,970
2	SANDOZ PTY LTD	26,482,518	20,877,508	47,360,026	\$494,811,142	\$153,556,321	\$648,367,463	\$331,769,207
3	ALPHAPHARM PTY LTD	26,565,468	13,498,599	40,064,067	\$479,971,574	\$148,611,015	\$628,582,589	\$306,614,794
4	ARROW PHARMA PTY LTD	19,956,523	9,308,504	29,265,027	\$344,899,991	\$98,305,852	\$443,205,843	\$192,063,409
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	9,994,425	6,403,476	16,397,901	\$171,957,003	\$65,699,819	\$237,656,823	\$119,429,655
6	WAGNER PHARMACEUTICALS PTY LTD	4,893,767	8,805,175	13,698,942	\$57,129,654	\$35,435,499	\$92,565,152	\$59,663,360
7	ARROTEX PHARMACEUTICALS PTY LTD	7,200,781	2,407,250	9,608,031	\$212,630,483	\$70,055,930	\$282,686,413	\$186,066,477
8	BOEHRINGER INGELHEIM PTY LTD	8,136,387	1,337,024	9,473,411	\$433,164,447	\$82,907,514	\$516,071,961	\$387,277,633
9	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,916,180	1,606,109	7,522,289	\$1,092,293,437	\$66,480,097	\$1,158,773,533	\$961,013,024
10	ASTRAZENECA PTY LTD	5,132,269	551,217	5,683,486	\$657,012,642	\$63,785,841	\$720,798,483	\$549,347,904
11	GLAXOSMITHKLINE AUSTRALIA PTY LTD	4,916,537	718,673	5,635,210	\$303,014,897	\$46,613,407	\$349,628,304	\$201,246,675
12	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,142,646	1,319,890	5,462,536	\$640,026,227	\$34,488,116	\$674,514,343	\$513,190,014
13	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	4,308,635	477,912	4,786,547	\$490,471,402	\$77,388,839	\$567,860,241	\$415,287,244
14	SERVIER LABORATORIES (AUST.) PTY. LTD.	2,624,140	1,854,133	4,478,273	\$45,579,012	\$14,572,237	\$60,151,250	\$32,122,367
15	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,322,784	1,907	4,324,691	\$428,612,850	\$44,564,851	\$473,177,701	\$365,854,363
16	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,981,674	247,796	4,229,470	\$502,049,059	\$57,963,668	\$560,012,728	\$469,233,137
17	PFIZER AUSTRALIA PTY LTD	2,375,202	961,860	3,337,062	\$651,298,190	\$24,252,813	\$675,551,003	\$607,313,832
18	VIATRIS PTY LTD	2,281,444	937,982	3,219,426	\$71,037,027	\$14,772,036	\$85,809,063	\$58,205,277
19	PHARMACOR PTY LIMITED	2,214,370	848,469	3,062,839	\$51,746,084	\$11,951,619	\$63,697,703	\$34,760,648
20	UPJOHN AUSTRALIA PTY LTD	1,571,319	1,364,438	2,935,757	\$26,683,335	\$8,479,855	\$35,163,190	\$19,719,872

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

Table 13: Number of PBS Approved Suppliers, 30 June 2025

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,927	54	0	1
VIC	1,437	46	74	1
QLD	1,232	43	53	0
SA	471	11	15	1
WA	663	7	23	4
TAS	161	6	5	0
NT	41	1	6	0
ACT	81	6	0	0
Total	6,013	174	176	7

Table 14(a): PBS Brand Premiums, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

	2024-25
Number of brands listed on the PBS ¹	5,371
Number of brands with a premium ¹	360
% of brands with a premium	6.7%
Average brand premium	\$8.00
Weighted average brand premium ²	\$5.71
Brand premium range	\$0.44 to \$39.40
Prescriptions (millions) dispensed on the PBS ³	187.9
Prescriptions (millions) dispensed with a brand premium	24.7
% of prescriptions dispensed with a brand premium	13.1%
Number of patients paying a brand premium	4,764,482
Number of patients not paying a brand premium	17,866,462
Total patients ⁴	18,257,568

¹ A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2025 PBS Schedule. Note this differs from cover page figure which includes Prescriber Bag.

² Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium


³ Includes only items where at least one brand is listed with a premium.

⁴ Total patients will not add to above rows as some patients will have received scripts with both a brand premium and without.

Table 14(b): Electronic PBS Prescriptions, 2024-25

Section 85 and Section 100, including under co-payment prescriptions, excluding Prescriber Bag

Prescription basis	PBS prescriptions	Percentage
Electronic Prescription	74,109,702	22.6%
ETP Prescription	187,920,109	57.3%
Paper-based Prescription	65,755,235	20.1%



Prescription type notes:

A prescriber will write an Electronic Prescription, and the prescription information is then sent to the National Prescription Delivery Service (NPDS).

The evidence of the Electronic Prescription is sent to the consumer as a unique electronic token (QR code) via SMS or email.

Electronic Transfer of Prescriptions (ETP) is the safe and secure transfer of paper prescription information, between a prescriber and a community pharmacy; using the NPDS and presents as a barcode (or sometimes a QR code) on the paper prescription and repeats.

Paper prescriptions are written by hand, or generated in clinical software, that is not connected to the NPDS.

Table 14(c): New PBS Drugs (by Active Ingredient), 2024-25

Section 85 and Section 100, including under co-payment prescriptions

Drug Name	Date listed	Indication or Main use	Prescriptions	Government Cost
AMIVANTAMAB	01MAY2025	Stage IIIB/ IIIC (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)	78	\$529,970
ANIFROLUMAB	01JUL2024	Systemic lupus erythematosus	1,048	\$1,506,708
AVACOPAN	01OCT2024	Anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis	1,334	\$11,272,397
BELZUTIFAN	01DEC2024	Von Hippel-Lindau (VHL) disease	334	\$7,384,848
CHLORMETHINE	01NOV2024	Mycosis fungoides cutaneous T-cell lymphoma	143	\$381,392
DAPAGLIFLOZIN + SITAGLIPTIN	01NOV2024	Diabetes mellitus type 2	5,177	\$316,895
DAUNORUBICIN + CYTARABINE	01JUL2024	Acute Myeloid Leukaemia	125	\$2,389,179
DIENOGEST	01DEC2024	Endometriosis	27,793	\$860,605
DROSPIRENONE	01MAY2025	Contraceptive	43,938	\$2,248,319
DROSPIRENONE + ETHINYLESTRADIOL	01MAR2025	Contraceptive	82,977	\$2,788,225
EDARAVONE	01MAY2025	Amyotrophic lateral sclerosis	13	\$71,307
EPCORITAMAB	01MAY2025	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	285	\$2,072,231
ESKETAMINE	01MAY2025	Treatment resistant major depression	518	\$2,108,691
ETRASIMOD	01OCT2024	Moderate to severe ulcerative colitis	754	\$1,059,607
FENFLURAMINE	01MAY2025	Severe myoclonic epilepsy in infancy (Dravet syndrome)	145	\$670,817
GLYCOMACROPEPTIDE FORMULA with AMINOACIDS and LOW PHENYLALANINE	01NOV2024	Phenylketonuria	12	\$15,674
GLYCOMACROPEPTIDE FORMULA with AMINO ACIDS, VITAMINS, MINERALS, TRACE ELEMENTS, CARBOHYDRATE, FAT and LOW PHENYLALANINE	01NOV2024	Phenylketonuria	5	\$10,317
ICOSAPENT ETHYL	01OCT2024	Established atherosclerotic cardiovascular disease with hypertriglyceridaemia	5,752	\$792,646
MACITENTAN + TADALAFIL	01MAY2025	Pulmonary arterial hypertension (PAH)	67	\$173,442
MELATONIN	01JUL2024	Insomnia	1,379	\$149,693
MIGALASTAT	01SEP2024	Fabry disease	579	\$16,241,653
MOMELOTINIB	01APR2025	High risk and intermediate-2 risk myelofibrosis Intermediate-1 risk myelofibrosis	653	\$3,770,835
OSILODROSTAT	01MAR2025	Endogenous Cushing's syndrome	186	\$970,307
PATISIRAN	01AUG2024	Hereditary transthyretin amyloidosis	320	\$10,302,731
PROGESTERONE (&) ESTRADIOL	01MAR2025	Hormone Replacement Therapy (HRT)	182,802	\$7,431,800
PROPYLENE GLYCOL	01APR2025	Severe dry eye syndrome	2,307	\$24,796
RELUGOLIX + ESTRADIOL + NORETHISTERONE ACETATE	01MAY2025	Endometriosis	4,332	\$805,146
SELPERCATINIB	01FEB2025	Locally advanced or metastatic non-small cell lung cancer	135	\$815,817
SELUMETINIB	01AUG2024	Neurofibromatosis type 1	344	\$4,889,768
TALAZOPARIB	01JAN2025	Castration resistant metastatic carcinoma of the prostate	7	\$25,178
TISLELIZUMAB	01APR2025	Advanced or metastatic gastro-oesophageal cancer	72	\$473,552
VUTRISIRAN	01MAY2025	Hereditary transthyretin amyloidosis	23	\$2,624,439

Further information on PBS items can be found on the PBS website (<https://www.pbs.gov.au>) and the TGA product repository (<https://www.tga.gov.au/resources/artg>)

Table 14(d): New PBS Drugs by ATC level 1, 2020-21 to 2023-24

Section 85 and Section 100, including under co-payment prescriptions

ATC 1 Name	2020-21		2021-22		2022-23		2023-24	
	New Drugs	Government Cost	New Drugs	Government Cost	New Drugs	Government Cost	New Drugs	Government Cost
ALIMENTARY TRACT AND METABOLISM	1	\$21,025,804	1	\$2,643,380	1	\$338,799	1	\$21,681
ANTIINFECTIVES FOR SYSTEMIC USE	0	\$-	4	\$76,348,313	0	\$-	0	\$-
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	8	\$49,124,462	10	\$36,532,605	10	\$79,746,701	8	\$83,380,472
BLOOD AND BLOOD FORMING ORGANS	0	\$-	1	\$11,829,434	0	\$-	1	\$4,518,647
CARDIOVASCULAR SYSTEM	1	\$4,492,974	1	\$877,189	1	\$263,593	3	\$5,951,884
DERMATOLOGICALS	2	\$22,812,402	0	\$-	0	\$-	0	\$-
GENITO URINARY SYSTEM AND SEX HORMONES	0	\$-	0	\$-	0	\$-	0	\$-
MUSCULO-SKELETAL SYSTEM	1	\$149,824	2	\$24,572,721	2	\$30,035,068	0	\$-
NERVOUS SYSTEM	3	\$3,265,856	2	\$16,667,321	2	\$1,978,681	2	\$9,461,992
RESPIRATORY SYSTEM	6	\$24,927,064	2	\$75,738,808	0	\$-	0	\$-
SENSORY ORGANS	0	\$-	4	\$15,170,696	1	\$35,881,471	0	\$-
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	0	\$-	0	\$-	3	\$2,020,082	0	\$-
VARIOUS	1	\$62,330	0	\$-	0	\$-	2	\$1,554,129

Table 15(a): PBS/RPBS discounted prescriptions dispensed by Community Pharmacies, 2024-25

Section 85 and Section 100, excluding Prescriber Bag and under co-payment prescriptions

	Concessional		General		RPBS		Total	
Prescription Type	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	31,276,537	16%	7,499,504	27%	713,119	10%	39,489,160	17%
Non-Discounted	163,093,156	84%	19,875,406	73%	6,096,313	90%	189,064,875	83%
Total	194,369,693	100%	27,374,910	100%	6,809,432	100%	228,554,035	100%

Table 15(b): PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2024-25

Section 85 and Section 100, excluding Prescriber Bag and under co-payment prescriptions

	Concessional		General		RPBS		Total	
Discount Range	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	12,997,484	41.6%	3,757,838	50.1%	279,120	39.1%	17,034,442	43.1%
\$0.50 - < \$1.00	17,956,140	57.4%	257,369	3.4%	426,142	59.8%	18,639,651	47.2%
< 50c	194,101	0.6%	3,470,142	46.3%	4,776	0.7%	3,669,019	9.3%
Other	128,812	0.4%	14,155	0.2%	3,081	0.4%	146,048	0.4%
Total	31,276,537	100.0%	7,499,504	100.0%	713,119	100.0%	39,489,160	100.0%

Table 16(a): PBS/RPBS Prescriptions for Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2024-25

Section 85, including under co-payment prescriptions

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	23,887	18,174	12,377	4,350	5,691	3,624	217	1,559	69,879
ANTIINFECTIVES FOR SYSTEMIC USE	428	248	321	92	140	84	-	45	1,358
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	338	220	243	41	78	87	-	55	1,062
BLOOD AND BLOOD FORMING ORGANS	2,419	1,456	1,712	448	603	369	23	208	7,238
CARDIOVASCULAR SYSTEM	120,192	90,743	54,032	20,058	26,575	17,429	977	6,532	336,538
DERMATOLOGICALS	185	111	86	19	27	35	-	14	477
GENITO URINARY SYSTEM AND SEX HORMONES	2,853	2,164	1,691	840	870	1,030	22	288	9,758
MUSCULO-SKELETAL SYSTEM	1,171	682	810	185	283	272	7	136	3,546
NERVOUS SYSTEM	6,782	4,387	6,039	1,108	1,798	2,106	40	947	23,207
RESPIRATORY SYSTEM	5,928	4,825	3,678	1,377	1,462	1,512	35	440	19,257
SENSORY ORGANS	824	566	437	94	190	122	-	50	2,283
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	643	426	479	124	163	166	-	63	2,064
VARIOUS	15	16	8	-	-	8	-	-	47
Total	165,665	124,018	81,913	28,736	37,880	26,844	1,321	10,337	476,714

Table 16(b): PBS/RPBS Government Cost for Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2024-25

Section 85, including under co-payment prescriptions

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$886,295	\$680,281	\$461,873	\$161,343	\$217,404	\$127,025	\$7,956	\$57,943	\$2,600,119
ANTIINFECTIVES FOR SYSTEMIC USE	\$35,169	\$20,314	\$12,578	\$50,693	\$2,658	\$1,015	\$-	\$6,049	\$128,476
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$119,395	\$48,662	\$147,514	\$45,095	\$21,800	\$70,994	\$-	\$18,491	\$471,951
BLOOD AND BLOOD FORMING ORGANS	\$82,926	\$53,879	\$63,067	\$15,773	\$22,111	\$12,419	\$994	\$8,372	\$259,541
CARDIOVASCULAR SYSTEM	\$1,203,108	\$840,084	\$578,746	\$190,837	\$267,390	\$172,860	\$7,270	\$54,572	\$3,314,868
DERMATOLOGICALS	\$22,089	\$2,442	\$21,523	\$3,780	\$428	\$5,735	\$-	\$223	\$56,221
GENITO URINARY SYSTEM AND SEX HORMONES	\$23,637	\$17,997	\$16,357	\$4,883	\$7,787	\$6,745	\$159	\$2,532	\$80,097
MUSCULO-SKELETAL SYSTEM	\$19,967	\$9,246	\$11,835	\$2,682	\$3,125	\$2,848	\$273	\$2,397	\$52,373
NERVOUS SYSTEM	\$107,229	\$60,704	\$113,139	\$12,995	\$18,097	\$36,472	\$454	\$13,186	\$362,275
RESPIRATORY SYSTEM	\$185,229	\$143,064	\$108,878	\$36,364	\$43,450	\$43,221	\$1,235	\$12,470	\$573,911
SENSORY ORGANS	\$19,670	\$9,236	\$11,770	\$1,441	\$3,059	\$1,981	\$-	\$643	\$47,800
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$8,627	\$4,650	\$8,129	\$1,260	\$1,940	\$2,205	\$-	\$754	\$27,566
VARIOUS	\$3,044	\$4,864	\$1,622	\$-	\$-	\$2,041	\$-	\$-	\$11,571
Total	\$2,716,384	\$1,895,423	\$1,557,032	\$527,148	\$609,250	\$485,560	\$18,340	\$177,632	\$7,986,768

Notes:

From 4 February 2025 to 31 March 2025, a temporary PBS Continued Dispensing Emergency Measure was put in place to support people affected by the flooding disaster in Far North Queensland and Tropical Cyclone Alfred to continue to access their PBS subsidised medicines. From 23 May 2025 to 30 June 2025, it was put in place again for the flooding disaster in New South Wales. Includes medicines listed under National Health (Continued Dispensing - Emergency Measures) Determination 2023, dispensed under ongoing or emergency measures. Small cells with counts less than 6 are suppressed and removed from the total.

Table 17(a): Remuneration for Community Pharmacies and Friendly Societies¹ for PBS subsidised prescriptions, 2023-24 and 2024-25
Section 85 and Section 100, including Prescriber Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2023-24	2024-25	Change	Percentage Change
Price to Pharmacists	Ex-Manufacturer Price	\$10,485,485,094	\$11,282,262,206	\$796,777,113	7.60%
	Wholesale Mark-up	\$538,278,028	\$550,983,709	\$12,705,681	2.36%
	Sub total	\$11,023,763,121	\$11,833,245,916	\$809,482,794	9.96%
Administration, Handling and Storage Costs	AHI fee	\$1,337,604,124	\$1,382,096,293	\$44,492,170	3.33%
	Sub total	\$1,337,604,124	\$1,382,096,293	\$44,492,170	3.33%
Pharmacist's Specialised Skills in Dispensing the Medicines	Dispensing Fee	\$1,903,299,670	\$1,963,994,028	\$60,694,358	3.19%
	Dangerous Drug Fee	\$54,841,245	\$63,454,868	\$8,613,623	15.71%
	Wastage	\$4,548,626	\$5,279,807	\$731,182	16.07%
	Container Fee	\$749,931	\$837,510	\$87,579	11.68%
	Sub total	\$1,963,439,472	\$2,033,566,214	\$70,126,742	46.65%
	Total²	\$14,324,806,717	\$15,248,908,423	\$924,101,706	6.45%

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$10,485,485,094	\$11,282,262,206	\$796,777,113	7.60%
Wholesale cost	\$538,278,028	\$550,983,709	\$12,705,681	2.36%
Pharmacy cost	\$3,301,043,596	\$3,415,662,507	\$114,618,911	3.47%
Total	\$14,324,806,717	\$15,248,908,423	\$924,101,706	6.45%

¹ Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both S85 and some S100 items. It includes Government and patient contributions.

* Includes EFC items dispensed by community pharmacies and friendly societies from March 2021

(EFC excluded prior to this as the pricing components were not available in the PBS online claims data).

* Includes private and public hospital HSD claims dispensed by community pharmacies and friendly societies.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

² Health's 2024-25 Annual Report lists the administered expenses for pharmaceutical benefits as \$19.3 billion. The difference between that figure and the total figure above is attributable to:

- * the annual report captures all S85 and S100 accrued expenses (including all HSDs and EFC), while the above data captures all S85 and some S100 data for community pharmacy and friendly societies only (it excludes a number of smaller S100 programs, for example the Opioid Dependence Treatment Program and Remote Area Aboriginal Health Services Program).
- * the annual report data is based on accrual figures, whilst the above data is cash basis;
- * the annual report does not include patient contributions;
- * the annual report data does not include the Electronic Prescription Fee;
- * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and
- * the annual report also excludes the items in the footnote 1 above.

Table 17(b): Pharmacy remuneration for PBS prescriptions by Formulary, 2023-24 to 2024-25

Section 85 and Section 100, including Prescriber Bag

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions		2023-24	2024-25	Change	Percentage Change
Price to Pharmacists	Ex-Manufacturer Price	F1	\$8,541,893,503	\$9,421,105,260	\$879,211,757	10.29%
		F2	\$3,329,887,741	\$3,432,160,266	\$102,272,525	3.07%
		CDL	\$1,666,959,070	\$1,536,627,775	-\$130,331,295	-7.82%
		Other	\$3,261,073	\$3,025,558	-\$235,515	-7.22%
	Wholesale Mark-up	F1	\$300,798,888	\$311,804,550	\$11,005,662	3.66%
		F2	\$243,210,676	\$249,603,506	\$6,392,831	2.63%
		CDL	\$60,576,468	\$55,636,125	-\$4,940,343	-8.16%
		Other	\$245,568	\$227,861	-\$17,707	-7.21%
	Sub total		\$14,146,832,987	\$15,010,190,901	\$863,357,915	6.10%
Administration, Handling and Storage Costs	AHI fee	F1	\$343,123,640	\$369,206,717	\$26,083,077	7.60%
		F2	\$1,410,216,016	\$1,431,282,870	\$21,066,854	1.49%
		CDL	\$76,028,428	\$72,235,036	-\$3,793,392	-4.99%
		Other	\$700,563	\$672,075	-\$28,488	-4.07%
	Sub total		\$1,830,068,647	\$1,873,396,699	\$43,328,051	2.37%
Pharmacist's Specialised Skills in Dispensing the Medicines	Dispensing Fee	F1	\$290,098,479	\$301,807,823	\$11,709,345	4.04%
		F2	\$2,405,788,968	\$2,450,523,575	\$44,734,607	1.86%
		CDL	\$92,178,525	\$95,093,557	\$2,915,032	3.16%
		Other	\$2,282,184	\$2,130,540	-\$151,643	-6.64%
	Dangerous Drug Fee	F1	\$19,795,007	\$25,881,263	\$6,086,255	30.75%
		F2	\$37,250,116	\$41,707,039	\$4,456,924	11.96%
		CDL	\$8,352,175	\$8,231,641	-\$120,534	-1.44%
		Other	\$1,782	\$2,631	\$849	47.67%
	Wastage	F1	\$1,846,188	\$2,280,039	\$433,851	23.50%
		F2	\$5,639,200	\$6,272,459	\$633,260	11.23%
		CDL	\$131,531	\$128,323	-\$3,208	-2.44%
		Other	\$3,229	\$3,277	\$48	1.47%
	Container Fee	F1	\$62,311	\$62,980	\$669	1.07%
		F2	\$1,638,447	\$1,805,022	\$166,575	10.17%
		CDL	\$12,352	\$11,833	-\$519	-4.20%
		Other	\$410	\$434	\$24	5.94%
	Sub total		\$2,865,080,905	\$2,935,942,439	\$70,861,534	2.47%
	Total²		\$18,841,982,539	\$19,819,530,039	\$977,547,500	5.19%

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	F1	\$8,541,893,503	\$9,421,105,260	\$879,211,757	10.29%
	F2	\$3,329,887,741	\$3,432,160,266	\$102,272,525	3.07%
	CDL	\$1,666,959,070	\$1,536,627,775	-\$130,331,295	-7.82%
	Other	\$3,261,073	\$3,025,558	-\$235,515	-7.22%
	Sub total	\$13,542,001,387	\$14,392,918,858	\$850,917,472	6.28%
Wholesale cost	F1	\$300,798,888	\$311,804,550	\$11,005,662	3.66%
	F2	\$243,210,676	\$249,603,506	\$6,392,831	2.63%
	CDL	\$60,576,468	\$55,636,125	-\$4,940,343	-8.16%
	Other	\$245,568	\$227,861	-\$17,707	-7.21%
	Sub total	\$604,831,600	\$617,272,043	\$12,440,443	2.06%
Pharmacy cost	F1	\$654,925,626	\$699,238,823	\$44,313,197	6.77%
	F2	\$3,860,532,747	\$3,931,590,966	\$71,058,219	1.84%
	CDL	\$176,703,012	\$175,700,391	-\$1,002,621	-0.57%
	Other	\$2,988,167	\$2,808,958	-\$179,210	-6.00%
	Sub total	\$4,695,149,552	\$4,809,339,137	\$114,189,585	2.43%
Total		\$18,841,982,539	\$19,819,530,039	\$977,547,500	5.19%

¹ Table 17(b) is for PBS and RPBS prescriptions claimed by all pharmacies for both S85 and S100 items. It includes Government and patient contributions. Given what data is and is not included, this table may not be directly comparable to other tables in this publication.

² Health's 2024-25 Annual Report lists the administered expenses for pharmaceutical benefits as \$19.3 billion.

The difference between that figure and the total figure above is attributable to:

* the annual report captures all S85 and S100 accrued expenses (including all HSDs and EFC), while the above data captures all S85 and S100 data for all pharmacy types (it excludes a number of smaller S100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).

* the annual report data is based on accrual figures, whilst the above data is cash basis;

* the annual report does not include patient contributions;

* the annual report data does not include the Electronic Prescription Fee;

* the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS

Table 18: CPA Professional Pharmacy Programs Expenditure, 2024-25

Under the Eighth Community Pharmacy Agreement (CPA) and other pharmacy programs operating at the end of the Seventh CPA, there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs in 2024-25 by relevant categories.

Program Category	Actual Expenditure
Eighth CPA Community Pharmacy Programs	\$275,217,154
Medication Management Review Programs	\$60,652,615
Rural Support and Aboriginal and Torres Strait Islander Pharmacy Programs	\$8,506,000
Pharmacy Programs administration fees	\$8,747,691
Programs Total	\$353,123,460

Notes:

1. For the Programs administration arrangements for 2024-25 the total funding provided to the Pharmacy Programs Administrator (i.e. Australian Healthcare Associates) was \$353,123,460. Of this, \$8,747,691 (GST excl) was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Programs Administrator administration fees was 2.48% of the total funds.

2. The program categories are made up of multiple elements, as per the following tables

Eighth CPA Community Pharmacy Programs consist of the following elements:	Actual Expenditure
Dose Administration Aids	\$122,541,240
Indigenous Dose Administration Aids	\$31,300,000
Staged Supply	\$10,719,914
Diabetes MedsCheck and MedsCheck	\$60,500,000
Rural Pharmacy Maintenance Allowance	\$50,156,000
Program Total	\$275,217,154

Medication Management services consist of the following elements:	Actual Expenditure
Residential Medication Management Review (RMMR)	\$17,152,615
Home Medicines Review (HMR)	\$30,900,000
Quality Use of Medicines (QUM)	\$12,600,000
Program Total	\$60,652,615

Rural Support and Aboriginal and Torres Strait Islander Pharmacy Programs consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$100,000
Emergency Locum Service	\$100,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$600,000
Undergraduate Pharmacy-Scholarship Scheme	\$600,000
CPE - Continuing Professional Education Allowance	\$380,000
Pharmacy - Rural Administration Support	\$360,000
Rural Pharmacy - Mentor Scheme	\$20,000
Post Intern Incentive Allowance	\$200,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$946,000
Rural Pharmacy Liaison Officer Program	\$720,000
Aboriginal and Torres Strait Islander Workforce (scholarships)	\$160,000
Aboriginal and Torres Strait Islander Workforce (traineeships)	\$120,000
Indigenous Health Services Pharmacy Support Program (IHSPS)	\$4,200,000
Program Total	\$8,506,000

Table 19: Actual Costs of Major Components of CPA*, 2024-25

Component	Expenditure
Pharmacy remuneration	\$3,415,662,507
Wholesale remuneration	\$550,983,709
Professional programs	\$353,123,460
Community Services Obligation (CSO)	\$256,088,174
Total	\$4,575,857,851

* The 8th CPA began on 1 July 2024 and will go to 30 June 2029

Notes:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Department of Health, Disability and Ageing receives from Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2024-25

Component	Expenditure
CSO funding pool	\$254,697,118
CSO admin	\$1,391,056
Total	\$256,088,174

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health, Disability and Ageing.

PBS INFORMATION LINE REPORT, 2024-2025

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2024 – 30th June 2025, the information line answered 4,429 calls. This was a decrease of 26.9% from the previous financial year, where 6,060 calls were answered.

Breakdown of calls by month:

Month	Number of calls
Jul-24	580
Aug-24	415
Sep-24	329
Oct-24	414
Nov-24	376
Dec-24	276
Jan-25	339
Feb-25	356
Mar-25	362
Apr-25	345
May-25	331
Jun-25	306
Total	4,429

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2021 until 30 June 2026.

The NDSS is managed by the Department of Health, Disability and Ageing through the Diabetes Support and CSO Section, in the Community Access Programs Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumables products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,800 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%
2020-21	443,572	1.19%	945,903	1.88%	1,389,475	1.65%
2021-22	466,014	5.1%	988,155	4.45%	1,454,169	4.7%
2022-23	466,481	0.10%	984,619	-0.36%	1,451,100	-0.21%
2023-24	481,336	3.18%	1,004,553	2.02%	1,485,889	2.04%
2024-25	493,069	2.43%	1,023,592	1.9%	1,516,661	2.07%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2024-25 financial year was \$346M. From 2016-17, NDSS Registrant co-payments for subsidised products, are now returned to Consolidated Revenue.

Abbreviations

Abbreviation	Definition
ABS	Australian Bureau of Statistics
AHI	Administration, Handling, and Infrastructure
ATC	Anatomical Therapeutic Chemical
CDL	Combination Drugs List
CPA	Community Pharmacy Agreement
CPI	Consumer Price Index
CSO	Community Services Obligation
CTG	Closing The Gap
DVA	Department of Veterans' Affairs
EFC	Efficient Funding of Chemotherapy
ETP	Electronic Transfer of Prescriptions
GST	Goods and Services Tax
HMR	Home Medicines Review
HSD	Highly Specialised Drugs
IRSAD	Index of Relative Socio-economic Advantage and Disadvantage
LBL	Line by Line
MMM	Modified Monash Model
NDSS	National Diabetes Services Scheme
NPDS	National Prescription Delivery Service
ODTP	Opioid Dependence Treatment Program
PBS	Pharmaceutical Benefits Scheme
QR	Quick -Response
QUM	Quality Use of Medicines
RACF	Residential Aged Care Facility
RMMR	Residential Medication Management Review
RPBS	Repatriation Pharmaceutical Benefits Scheme
S100	Section 100
S85	Section 85
SAP	Systems, Applications, and Products
SEIFA	Socio-Economic Indexes for Areas
SPA	Special Pricing Arrangements
TGA	Therapeutic Goods Association

Technical Notes

Unless otherwise indicated this publication has been produced using data provided to the Department of Health, Disability and Ageing by Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by approved suppliers. Claims of manually processed PBS programs are excluded.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by Services Australia. The historical data from 1948-49 to 2015-16 in Table 21(a) and Table 21(b) remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) and Table 21(b), because of a past problem in supply data whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed from 2008-09 onwards, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Remote Area Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 2.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Expenditure on nusinersen and onasemnogene abeparvovec was adjusted to include manual payments that were not processed through the PBS Online system.

The PBS Prescriber Bag is an additional patient category, which enables prescribers to obtain listed pharmaceutical benefits without charge from approved suppliers. Prescribers can then supply these PBS medicines free of charge to patients for immediate administration or emergency use.

Revenue is collected through various arrangements including Special Pricing Arrangements (SPA) under PBS medicine pricing deeds of agreement. Government Cost presented in this report does not include Revenue.

PBS data does not capture over-the-counter drugs, private prescriptions (non-PBS) or public inpatient prescriptions.

The Department of Health, Disability and Ageing has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.